



FORM PTO-1390 (REV. 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER I0317/7001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/890891
INTERNATIONAL APPLICATION NO. PCT/GB00/00414	INTERNATIONAL FILING DATE 09 February 2000 (09.02.00)	PRIORITY DATE CLAIMED 09 February 1999 (09.02.99)	
TITLE OF INVENTION MODULATOR OF INFLAMMATION			
APPLICANT(S) FOR DO/EO/US KNIGHT, Julian Charles; KWIATKOWSKI, Dominic Peter			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the earliest claimed priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11. To 16. Below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment w/ Appendix A and with Substitute Sheets			
14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
15. <input type="checkbox"/> A substitute specification.			
16. <input type="checkbox"/> A change of power of attorney and/or address letter.			
17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.			
18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).			
20. <input checked="" type="checkbox"/> Other items or information:			
Copy of PCT Published Application with International Search Report			
Copy of Written Opinion			
Copy of Response to Written Opinion			
Copy of International Preliminary Examination Report with Amended Claims (Claims 1-41)			
Statement Pursuant to 37 CFR 1.821(f) w/ diskette and paper copy of sequence listing (20 pages)			
Express Mail Label No. EL819461964US			
Date Mailed: August 7, 2001			

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 09/890891		INTERNATIONAL APPLICATION PCT/GB00/00414		ATTORNEY'S DOCKET NUMBER 10317/7001	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee paid to USPTO (37 CFR 1.445(a)(2)), paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) But all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = 860.00				CALCULATIONS <small>PTO USE ONLY</small>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$860.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	18-20 =	0	X \$18.00	\$	
Independent Claims	10-3 =	7	X \$80.00	\$560.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS				= \$1420.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL				= \$1420.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE				= \$1420.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate coversheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED				= \$1420.00	
				Amount to be: \$	
				refunded	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1420.00</u> To cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ In the amount of \$ _____ To cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO WOLF, GREENFIELD & SACKS, P.C. 600 Atlantic Avenue Boston, Massachusetts 02210 Tel: (617) 720-3500			SIGNATURE  Elizabeth R. Plumer NAME 36,637 REGISTRATION NO		
 23628					
CUSTOMER NUMBER					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Julian Charles KNIGHT et al.
U.S. Serial No.: Not yet assigned
International Application No. : PCT/GB00/00414
International Filing Date : 09 February 2000 (09.02.00)
Earliest Priority Date : 09 February 1999 (09.02.99)
Title : MODULATOR OF INFLAMMATION

Commissioner for Patents
Box PCT
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the United States national phase application of the above-identified PCT international application as follows.

In the Specification

Please add the following section as the first section of the specification following the title.

Related Applications

This application is a national stage filing 35 U.S.C. §120 or 35 U.S.C. §365(c) of PCT International application PCT/GB00/00414 designating the United States of America, and filed February 9, 2000, of which this application is a national stage filing under 35 U.S.C. §371, was published under PCT Article 21(2) in English.

Foreign priority benefits are claimed under 35 U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of British application number 9902919.1 filed February 9, 1999, which designated at least one country other than the United States.

Substitute Specification Pages

The specification is amended to reference the Related Applications, to insert Headings, to insert Sequence ID numbers, and to correct typographical errors. Substitute pages of the specification are attached hereto. Please substitute specification pages 1, 1A, 3, 3A, 4, 4A, 6, 7, 11, 12, 18, 18A, 19, 19A, 20, 21, 21A, 24, 25, 28, 30, 32, 32A, 33, and 33A

for original specification pages 1, 3, 4, 6, 7, 11, 12, 18, 19, 20, 21, 24, 25, 28, 30, 32, and 33, presently of record.

A marked up copy of the specification amendments is attached as Appendix A to facilitate the Examiner's review.

In the claims

The pending claims are those which were the subject of the IPER in the International Phase; however, please cancel claims 3, 6, 9, 11, 14, 16-22, 25-27, 30-32, and 37-41 before calculating the filing fee.

In the Sequence Listing

A substitute Sequence Listing is submitted herewith. Please substitute the substitute Sequence Listing for the one which presently is in the application.

Remarks


Applicants have amended the specification to provide priority application information and information regarding the publication in English under PCT Article 21(2) of the PCT application of which the above-identified application is a U.S. national stage application. No new matter has been added.

Applicants have cancelled selected claims solely for the purpose of reducing the filing fees. Applicants reserve the right to pursue the subject matter of the cancelled claims in this or one or more continuing applications.

Applicants have amended the Sequence Listing to include sequences disclosed in Application but not previously assigned SEQ ID NOs. No new matter has been added.

Respectfully submitted,

Julian Charles KNIGHT et al., Applicants



By: Elizabeth R. Plumer, Reg. No. 36,637
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel: (617) 720-3500

Attorney Docket No.: I0317/7001 (ERP)
Dated: 07 August 2001

Sub Spec.

- 1 -

JC03 Rec'd PCT/PTC

09/890891

07 AUG 2001

MODULATOR OF INFLAMMATION

Related Applications

This application is a national stage filing 35
5 U.S.C. §120 or 35 U.S.C. §365(c) of PCT International
application PCT/GB00/00414 designating the United
States of America, and filed February 9, 2000, of
which this application is a national stage filing
under 35 U.S.C. §371, was published under PCT Article
10 21(2) in English.

Foreign priority benefits are claimed under 35
U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of British
application number 9902919.1 filed February 9, 1999,
which designated at least one country other than the
15 United States.

The present invention is concerned with a
specific molecular mechanism by which inflammation and
susceptibility to infectious disease may be
genetically regulated, more specifically with a
20 molecular mechanism modulating the expression of
tumour necrosis factor- α (TNF- α). In particular, the
invention relates to two novel DNA binding proteins
which bind specifically to DNA target sites in the
TNF- α promoter region, to assays based on this
25 protein/DNA interaction and to a method of screening
for susceptibility to inflammatory disease based upon
screening for a polymorphism in the TNF- α promoter.

Background

30 Tumour necrosis factor- α is a pro-inflammatory
cytokine believed to play an important role in the
pathogenesis of many inflammatory and severe
infectious diseases. An example of a disease whose
severity is known to be associated with TNF- α is fatal
35 cerebral malaria which occurs in a small proportion of
individuals infected with the malaria parasite

- 1A -

Plasmodium falciparum. Clinical studies of cerebral malaria patients have demonstrated an association between host TNF- α levels and disease severity (Grau, G. E. et al. (1989) *New Engl. J. Med.* **320**: 1586-1591; 5 Kwiatkowski, D. et al (1990) *Lancet* **336**: 1201-1204; Kern P. et al. (1989) *Am. J. Med.* **57**: 139-143) and experimental studies have revealed several ways in which excessive TNF- α production could promote cerebral malaria (Clark, I. A. (1987) *Parasitol. Today* 10 **3**: 300-305; Grau, G. E. et al. (1987) *Science* **237**: 1210-1212).

In humans the gene for TNF- α resides within the class III region of the major histocompatibility complex (MHC) and several studies have shown that

it remains an open question as to whether the disease associations with polymorphisms in the TNF- α promoter region are due to a direct effect on the TNF- α gene regulation, as opposed to linkage disequilibrium with functional polymorphisms elsewhere in the TNF- α locus or neighbouring genes.

Summary

The present inventors have surprisingly found that one of the known polymorphisms in the TNF- α promoter region is located within a site of DNA/protein recognition and thus has a direct functional effect on TNF- α transcription via altered transcription factor recruitment. The present inventors have further identified two novel DNA binding proteins which specifically recognise DNA sites in the region of the TNF- α promoter surrounding this polymorphism.

Accordingly, in a first aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2.

Most preferably this protein, hereinafter referred to as the 21kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 21 +/-5kDa when run on an SDS PAGE denaturing gel.

In a second aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 3.

Most preferably this protein, referred to hereinafter as the 30kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 30kDa +/- 5kDa when run on an SDS PAGE denaturing gel.

- 3A -

The invention also provides isolated nucleic acids having the nucleotide sequences illustrated in

SEQ ID NO: 1 or SEQ ID NO: 2 or fragments thereof which are capable of specifically binding the above-described 21kDa DNA binding protein.

5 The invention also provides an isolated nucleic acid having the nucleotide sequence illustrated in SEQ ID NO: 3 a fragment thereof which is capable of binding specifically to the above-described 30kDa DNA binding protein.

10 The proteins of the invention are DNA binding proteins which have been characterised as binding specifically to DNA sequences within the promoter region of the TNF- α gene. As will be described in Example 2, the binding sites for these proteins were identified on the basis of solid phase DNAase I
15 footprinting analysis of the region of the TNF- α promoter spanning positions -682 to -183 relative to the transcription start site using nuclear extracts from the cell line MonoMac6 which phenotypically resembles a well-differentiated human monocyte
20 (Ziegler-Heitbrock, H.W.L. *et al* (1988) *Intl. J. Cancer* **41**: 456-461). The precise position of the protein binding sites has been further elucidated using electrophoretic mobility shift assays (EMSA) as will be described in detail in Example 3 below. Thus,
25 the novel 21kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -391 to position -374 relative to the transcription start site, having the nucleotide sequence set forth in Figure 1a (SEQ ID NO: 1). This
30 region, which includes the previously identified -376 G/A polymorphism, is hereinafter referred to as the α site. The novel 30kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -365 to position
35 -352 relative to the transcription start site, having the nucleotide sequence set forth in Figure 2 (SEQ ID NO: 3). This region is hereinafter referred to as the

interaction will result in an absence of the band corresponding to the complex in a similar manner to the competition experiments described in Example 3. The steps of "observing the presence or absence of
5 complexes" might include simple qualitative detection of such complexes or quantitative measurement.

The invention also provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:
10 contacting a DNA-protein complex comprising one of the following DNA/protein combinations:

- (i) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2 and the 21kDa DNA binding protein,
- 15 (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3 and the 30kDa DNA binding protein,
- (iii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2, the
20 21kDa DNA binding protein and the transcription factor protein Oct-1,

with a sample of the compound and observing whether the DNA-protein complex is disrupted following contact with the compound.

25 In a further aspect the invention provides a method of identifying a compound capable of modulating TNF- α gene expression, which method comprises contacting a fragment of DNA comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO:
30 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequences from the TNF- α promoter with a sample of the compound and detecting specific binding of the compound to the fragment of DNA.

35 The method of the invention is used to identify compounds capable of specifically binding to the α and β sites within the TNF- α promoter, which compounds may

thus be useful as modulators of the TNF- α transcription. Such compounds may be useful therapeutically in clinical situations in which it is desirable to up-regulate or down-regulate levels of
5 TNF- α .

In order to isolate compounds which interact specifically the α and/or the β site, the method of the invention uses α and β site sequences isolated from the remainder of the TNF- α promoter, i.e. in the
10 substantial absence of any other nucleotide sequences from the TNF- α promoter.

The readout of the assays of the invention may be provided by any technique known in the art to be useful in the detection of specific DNA/protein
15 binding. Preferably, the DNA fragments of interest are labelled, either with biochemical markers or radioisotopes and binding of compounds is screened by techniques such as, for example, electrophoretic mobility shift assay (EMSA). Alternatively, specific
20 binding interactions can be detected, without the need of labels, by proximity assay techniques such as, for example, flow cytometry or surface plasmon resonance. Advantageously, the assay method of the invention may be used to screen a combinatorial library of compounds
25 in order to identify any compounds capable of specifically binding to site α or site β .

In a still further aspect the invention provides a reporter gene expression construct comprising:

a reporter gene encoding a transcriptional and/or
30 translational product which can be directly or indirectly detected; and

a transcriptional control element comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the
35 substantial absence of any other nucleotide sequence from a TNF- α promoter, the transcriptional control element being operably linked to the reporter gene.

the art, genotyping is generally carried out on genomic DNA prepared from a suitable tissue sample obtained from the subject under test. Most commonly, genomic DNA is prepared from a sample of whole blood,
 5 according to standard procedures which are well known in the art.

Brief Description of the Drawings

The present invention may be further understood
 10 with reference to the following Examples together with the accompanying Figures in which:

Figure 1 shows the nucleotide sequence of the TNF- α promoter from position -391 to position -374 relative
 15 to the transcription start site, corresponding to the α site; 1a is the wild type TNF-_{376G} allele (SEQ ID NO: 1), 1b is the polymorphic variant TNF-_{376A} allele (SEQ ID NO: 2).

20 Figure 2 shows the nucleotide sequence of the TNF- α promoter from position -365 to position -352 relative to the transcription start site, corresponding to the β site (SEQ ID NO: 3).

25 Figure 3 shows the results of a solid phase DNAase I footprinting experiment using a radiolabelled probe spanning the region from position -682 to position -183 of the TNF- α promoter, in the absence of nuclear
 30 extract (lanes 2 and 5) or incubated with nuclear extracts prepared from unstimulated MonoMac6 cells (lane 3) or MonoMac6 cells stimulated with lipopolysaccharide (LPS) (lane 4). Lane 1 is the Maxam Gilbert sequencing ladder for the same region of the TNF- α promoter.

35

Figure 4 shows the probes used in an electrophoretic mobility shift assay (EMSA) investigating the precise

10

Figure 7 shows the probes used in an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region (SEQ ID NO: 30). β corresponds to the sequence from nucleotide -372 to nucleotide -352 of the TNF- α promoter (SEQ ID NO: 5); β -1 corresponds to the sequence from nucleotide -365 to nucleotide -345 of the TNF- α promoter (SEQ ID NO: 31); β -2 corresponds to

- 20 -

Figure 8 shows the results of electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region. Nuclear extracts from LPS stimulated (lane 3) or unstimulated (lane 2 and 4-14) MonoMac6 cells were incubated with a radiolabelled β (lane 2, 3 and 11), β -1 (lane 13) or β -2 (lane 14) probe. A competition assay was also performed with a radiolabelled β probe in the presence of a 10x molar excess of an unlabelled β (lane 4), β -1 (lane 8), β -2 (lane 10) or EGR site F:agctAAATCCCCGCCCCGCGATGGA) (SEQ ID NO: 10) (lane 6) probe or in the presence of a 100x molar excess of unlabelled β (lane 5), β -1 (lane 9), β -2 (lane 11) or EGR site (lane 7) probe.

Figure 9 shows the results of UV-crosslinking experiments investigating proteins binding at the α and β sites of the TNF- α promoter. EMSA binding reactions were performed with radiolabelled double stranded oligonucleotide probes comprising the α site (with G or A at position -376, for complex I and II respectively) or the β site (complex III), in which five dT nucleotides were substituted with BrdU (as shown in Figure 10 below), complexes were crosslinked by UV light, excised and resolved using a 4-12% gradient polyacrylamide gel, either (a) directly or (b) after immunoprecipitation with anti-Oct-1 or control antibody.

Figure 10 shows the nucleotide sequence of the probes used in the cross-linking experiment described in Example 4. 5BrdU is shown as a Q.

Figure 11 is an EMSA using the β site specific probe (see below) illustrating the enrichment of proteins binding to site β of the TNF- α promoter using a P11

column: Lane 1 crude nuclear extract, lane 2 crude nuclear extract following incubation with P11, lane 3 low salt buffer wash of P11, lane 4 enriched material eluted from P11 with high salt buffer.

5

Figure 12 is an EMSA using the β site specific probe (see below) illustrating the purification of proteins which bind specifically to site β of the TNF- α promoter using DNA affinity purification: Lane 1
10 heparin sepharose enriched material, lane 2 bead-DNA purified material.

Detailed Description

Example 1 Preparation of Nuclear Extracts

15

MonoMac6 cells ($10-20 \times 10^6$) maintained in culture as previously described (Ziegler-Heitbrock, H. W. L. et al. *Int. J. Cancer*. **41**: 456-461 (1988)) were either harvested unstimulated or stimulated with 100ng/ml
20 lipopolysaccharide (LPS) for 1 hour and then harvested. Nuclear extracts were prepared according to the method of Schrediber, E. et al. *Nucleic Acids Res.* **17**: 6419 (1989).

25

Example 2 Solid Phase DNAase I Footprinting.

Experimental method

Radiolabelled probes spanning the TNF- α promoter region from position -682 to position -183 relative to
30 the transcription start site were generated by PCR using antisense primer 5'-GTTGGGGACACACAAGCATC (SEQ ID NO: 11) (end labelled with $\gamma^{32}\text{P}$ -dATP using T4 polynucleotide kinase) and biotinylated primer 5'-GCATTATGAGTCTCCGGGTC (SEQ ID NO: 12) using TNFwt
35 (-1173)-pXP1 plasmid DNA as template (construction of this plasmid is described in Example 5 part (A) below. The DNAase I footprinting procedure itself was carried

- 21A -

out according to the technique

b) Characterisation of complex II

The nature of complex II was further investigated by an EMSA supershift and competition assay, the results of which are shown in Figure 6. Complex II but not complex I was neutralised by the presence of antibody to Oct-1 (lanes 2 and 9) whilst neither complex was affected by anti-p50 (lanes 3 and 10). Complex I was competed by 100x molar excess of probe α_G (lane 4) or probe α_A (data not shown), both shown in Figure 4, but not by 100x molar excess of an oligoduplex probe matching an Oct-1 binding site from the human histone 2b gene (F:agctTCGCTTATGCAAATAAGGTGA) (SEQ ID NO: 13) (lanes 5 and 6) or a probe matching the EGR site (F:agctAAATCCCCGCCCCGCGATGGA) (SEQ ID NO: 10) (lane 7). In contrast, complex II was competed by a molar excess of α_A (lane 11) and the probe matching the Oct-1 (lanes 12 and 13) but not by the probe matching the EGR site (lane 14) or probe α_G (data not shown). The EMSA supershift and competition data indicate that in the presence of TNF-_{376A} allele but not the presence of the TNF-_{376G} allele Oct-1 binds to the α site in addition to the 21kDa protein to form complex II.

c) Precise localisation of β site

In order to identify the precise region of the TNF- α promoter corresponding to the β site, an EMSA assay was carried out as described above, utilising the probes shown in Figure 7. Figure 8 shows that formation of a complex (complex III) was observed with the β (lanes 2,3 and 12) and β -1 (lane 13) probes but not with the β -2 probe (lane 14). Furthermore, formation of complex III with the β probe was competed by a molar excess of the β (lanes 4 and 5) or the β -1 (lanes 8 and 9) probe but not by the

- 25 -

β -2 probe (lanes 10 and 11) or by an irrelevant probe (lanes 6 and 7).

These results, combined with those obtained from the Footprinting experiment of Example 2, suggest that the β site is localised between nucleotide -365 and -352 of the TNF- α promoter region.

Example 4 UV-crosslinking

Experimental methods

UV-crosslinking was carried out by first performing EMSA experiments using radiolabelled oligoduplex probes (SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38) in which specified dT nucleotides were substituted with BrdU, as shown in Figure 10. The EMSA gel was then illuminated with UV radiation at 302nm for 30 minutes at 4°C and exposed to autoradiography film for four hours at the same temperature. The autoradiography film was used to locate regions of the EMSA gel corresponding to the specific protein-DNA complexes. The relevant fragments of gel were then excised and the complexes eluted in 2x SDS buffer (100mM Tris-Cl pH 6.8, 200mM DTT, 2% SDS, 20% glycerol) at 37°C overnight. The complexes thus isolated were then resolved using a 4-12% gradient polyacrylamide gel either directly or after immunoprecipitation as previously described (Hansen, S.K. et al. *EMBO J.* **11**: 205-213).

Results

Figure 9 shows the results of UV-crosslinking experiments to investigate proteins binding at site α and β of the TNF- α promoter using α and β site oligoduplex probes. Figure 9(a) 4-12% gradient SDS-PAGE of complexes formed by incubation of crude

Table 1

	No Insert	376G	376A	P Value*
Basal	0.23±0.07	16.1±1.7	21.7±2.4	0.002
LPS-stimulated	0.25±0.1	189.9±19.3	200.3±13.7	ns
Ratio of LPS stimulated: basal	1.1±0.5	12.3±1.4	10.1±1.5	0.007

*P values shown for comparison of 376G and 376A constructs by two-tailed paired t-test. MonoMac6 cells were transfected with pXP1 vector containing no insert, which served as a negative control, or with one of two allelic forms of the TNF- α promoter region which differed by a single nucleotide substitution at position -376, either G (denoted as 376G) or A (denoted as 376A). The mean of 7 independent transient transfection experiments is shown (\pm SEM) using two independent plasmid preparations. Cells were unstimulated to determine basal expression or stimulated with a high dose of LPS (200ng/ml). Luciferase activity of cell lysates was determined using a luminometer (with results corrected for total cell protein) and is expressed as luminometer units per mg protein.

Example 6 Clinical case-control studies.

(A) Study design

Children under 10 years of age were recruited to two independent case-control studies in the Gambia and Kenya. The Gambian study was carried out near Banjul and was hospital based as described previously (Hill, A.V.S. et al. (1991) *Nature* **352**: 595-600). In the Kenyan study cases of severe malaria recruited at the

nucleotide product spanning position -558 to position -183 of the TNF- α promoter using 100ng of genomic DNA as a template. This product was alkaline denatured and hybridised in streptavidin coated microtitre plates with allele-specific 5' biotinylated oligonucleotide probes at 55°C for 2 hours. Allele-specific capture probes used for TNF-₂₃₈ were 5'-CCTCGGAATCgGAGCAGGGA (SEQ ID NO: 14) and 5'-CCTCGGAATCaGAGCAGGGA (SEQ ID NO: 15) at 2.5 pmol/ml; for TNF-₃₇₆ 5'-CTGTCTGGAAGTTAGAAGGA (SEQ ID NO: 16) and 5'-CTGTCTGGAAaTTAGAAGGA (SEQ ID NO: 17) at 15 pmol/ml. A split plate design was used for each polymorphism, including positive and negative controls. Hybridised DNA was labelled by incubation with 2mU anti-digoxigenin peroxidase conjugate for 30 minutes at 37°C. After addition of 0.2mg of ABTS substrate plates were read on an ELISA plate reader at 405nm (reference filter 492nm). The accuracy of genotyping data obtained by PCR ELISA was confirmed by DNA sequencing.

Results

Results from the Gambian case control study are summarised in Table 2 below:

Table 2

	Cerebral malaria	Severe malaria anaemia	Mild malaria	Non- malaria controls
TNF-_{376A}				
<i>n</i>	384	132	349	371
Heterozygotes	24 (6.3%)	5 (3.8%)	13 (3.7%)	9 (2.4%)
Homozygotes	1 (0.3%)	0	1 (0.3%)	1 (0.3%)

n number of individuals in each clinical category for the Gambian case-control study. In a 2x2 analysis

site α

5'agctGTTCTATCTTTTCCTGCATCCTGTCTGGAAGTTA (SEQ ID
NO: 18)

5'agctTAACTTCCAGACAGGATGCAGGAAAAAGATAGAAC (SEQ ID
5 NO: 19)

site β

5'agctTAGAAGGAAACAGACCACAGACCTG (SEQ ID NO: 20)

5'agctCAGGTCTGTGGTCTGTTTCCTTCTA (SEQ ID NO: 21)

10

Crude nuclear extract prepared from unstimulated U937
cells will bind to heparin sepharose CL-6B (Pharmacia)
and to phosphocellulose (P11) (Whatman) using BC100
buffer (20mM Hepes, 20% glycerol, 0.2mM EDTA and 100mM
15 NaCl). The active material containing the protein(s)
binding to site β are eluted by applying a salt
gradient from 100 to 2000mM with enriched material
eluted at 250-350mM (heparin sepharose) and 500-600mM
(P11) BC buffer. Figure 11 illustrates this for P11
20 in an EMSA: lane 1 crude nuclear extract, lane 2 crude
nuclear extract following incubation with P11
(demonstrating the protein is absent as it has bound
to P11), lane 3 low salt buffer wash of P11
(demonstrating the protein remains bound to P11), lane
25 4 enriched material eluted from P11 with high salt
buffer.

2) DNA affinity purification

Following heparin sepharose/P11 purification, the
30 proteins binding to sites α and β are recovered by DNA
affinity purification using site-specific
oligonucleotide probes. The generic methodology for
purification using biotinylated oligonucleotide probes
linked to streptavidin coated beads has been described
35 (Nucleic Acids Research 17, 6253-6267 (1989)).
For site β the following biotinylated probe is

- 32A -

synthesised:

5'agctTAGAAGGAAACAGACCACAGACCTG (SEQ ID NO: 22)
ATCTTCCTTTGTCTGGTGTCTGGAC-biotin-5' (SEQ ID NO: 23)

For site α the following biotinylated probe is synthesised:

5'agctGTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA (SEQ ID NO:
 5 24)
 CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-biotin-5
 (SEQ ID NO: 25)'

Procedures for the labelling of oligonucleotides
 10 with biotin are well known in the art.

The appropriate double-stranded probe is added to streptavidin-coated DynabeadsJ (M-280) to which the probe becomes strongly bound. Incubation of the probe-bead complex with the enriched material
 15 generated in part 1) allows binding of the proteins specific to the site of interest defined by the sequence of the oligonucleotide probe. Figure 12 shows the result of such a purification step for site β when the products are used in an EMSA (lane 1
 20 heparin sepharose purified material, lane 2 bead-DNA purified material).

SEQUENCE LISTING

1. Sequence ID No. 1 corresponds to the nucleotide
 25 sequence of the α site of the human TNF- α promoter illustrated in Figure 1a (TNF-_{376G} allele).
2. Sequence ID No. 2 corresponds to the nucleotide
 30 sequence of the α site of the human TNF- α promoter illustrated in Figure 1b (TNF-_{376A} allele).
3. Sequence ID No. 3 corresponds to the nucleotide
 35 sequence of the β site of the human TNF- α promoter illustrated in Figure 2.

4. Sequence ID No. 4 is the nucleotide sequence of

<110> KNIGHT, Julian Charles
KWIATKOWSKI, Dominic Peter

<120> MODULATOR OF INFLAMMATION

<130> I0317/7001 ERP/RE/CSM

<140> Not assigned yet

<141> 2001-08-07

<150> PCT/GB00/00414

<151> 2000-02-09

<160> 38

<170> PatentIn version 3.1

<210> 1

<211> 18

<212> DNA

<213> Homo sapiens

<400> 1
gcacccctgtc tggaagtt

<210> 2

<211> 18

<212> DNA

<213> Homo sapiens

<400> 2

gcacccctgtc tggaaatt

18

<210> 3

<211> 14

<212> DNA

<213> Homo sapiens

<400> 3

acagaccaca gacc

14

<210> 4

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence:
oligonucleotide containing binding site
for the 21kDa DNA binding protein

<400> 4

gttctatcctt tttcctgcat cctgtctgga agtta

35

<210> 5

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 30kDa DNA binding protein

<400> 5
tagaaggaaa cagaccacag acctg 25

<210> 6

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide probe for PCR ELISA

<400> 6
ctgtctggaa gttagaagga 20

<210> 7

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide probe for PCR ELISA

<400> 7
ctgtctggaa attagaagga 20

<210> 8

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 21kDa DNA binding protein

<400> 8

caagatagaa aaaggacgta ggacagacct tcaat

35

<210> 9

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 30kDa DNA binding protein

<400> 9

atcttccttt gtctggtgtc tggac

25

<210> 10

<211> 26

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: EGR site

<400> 10

agctaaatcc cgcggggc gatgga

26

<210> 11

<211> 20

25

<210> 14

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 14
cctcgggaatc ggagcagggga 20

<210> 15

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 15
cctcgggaatc agagcagggga 20

<210> 16

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 16
ctgtctggaa gttagaagga 20

<210> 17

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 17

ctgtctggaa attagaagga

20

<210> 18

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe designed to bind to alpha
site

<400> 18

agctgttcta tctttttcct gcacccctgtc tggaagtta

39

<210> 19

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe designed to bind to alpha
site

<223> Description of Artificial Sequence: Beta site probe

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Alpha site probe

<220>

<221> misc_binding

<222> (35)..(35)

<223> biotin

<400> 25

caagatagaa aaaggacgta ggacagacct tcaat

35

<210> 26

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe alpha-A

<400> 26

gttctatctt tttcctgcat cctgtctgga aatta

35

<210> 27

<211> 22

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe distal alpha

$\langle 220 \rangle$

<400> 32

cacagacctg gtccccaaaa g

21

<210> 33

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-G

<220>

<221> modified_base

<222> (16)..(16)

<223> 5BrdU

<220>

<221> modified_base

<222> (20)..(20)

<223> 5BrdU

<220>

<221> modified_base

<222> (27)..(27)

<223> 5BrdU

<220>

<221> modified_base

<222> (31)..(31)

<223> 5BrdU

<220>

<221> modified_base

<222> (37)..(37)

<223> 5BrdU

<400> 33

agctgttcta tctttttcct gcacccctgc tggaagtta

39

<210> 34

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site al
pha-G

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe

<220>

<221> modified_base

<222> (5)..(5)

<223> 5BrdU

<220>

<221> modified_base

<222> (9) .. (10)

<223> 5BrdU

<220>

<221> modified_base

<222> (21) .. (21)

<223> 5BrdU

<220>

<221> modified_base

<222> (34) .. (34)

<223> 5BrdU

<400> 34

agcttaactt ccagacagga tgcaggaaaa agatagaac

39

<210> 35

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-G

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-A

$\langle 220 \rangle$

```
<221> modified_base
```

$\langle 222 \rangle \quad (16) \dots (16)$

<223> 5BrdU

$\langle 220 \rangle$

```
<221> modified_base
```

$\langle 222 \rangle \quad (20) \dots (20)$

<223> 5BrdU

<220>

```
<221> modified_base
```

<222> (27) . . (27)

<223> 5BrdU

 $\langle 220 \rangle$

```
<221> modified_base
```

<222> (31) . . (31)

<223> 5BrdU

<220>

```
<221> modified_base
```

<222> (37) .. (37)

<223> 5BrdU

<400> 35

agctgttcta tcttttttcct gcatacctgtc tggaaatta

39

<210> 36

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-A

<220>

<221> modified_base

<222> (5) .. (5)

<223> 5BrdU

<220>

<221> modified_base

<222> (8) .. (8)

<223> 5BrdU

<220>

<221> modified_base

<222> (10) .. (10)

<223> 5BrdU

<220>

<221> modified_base

<222> (21)..(21)

<223> 5BrdU

<220>

<221> modified_base

<222> (34)..(34)

<223> 5BrdU

<400> 36

agcttaattt ccagacagga tgcaggaaaa agatagaac

39

<210> 37

<211> 29

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site beta

<220>

<221> modified_base

<222> (5)..(5)

<223> 5BrdU

<220>

<221> modified_base

<222> (28)..(28)

<223> 5BrdU

<400> 37

agcttagaag gaaacagacc acagacctg

29

<210> 38

<211> 29

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site beta

<220>

<221> modified_base

<222> (13)..(13)

<223> 5BrdU

<220>

<221> modified_base

<222> (16)..(16)

<223> 5BrdU

MODULATOR OF INFLAMMATIONRelated Applications

5 This application is a national stage filing 35
U.S.C. §120 or 35 U.S.C. §365(c) of PCT International
application PCT/GB00/00414 designating the United
States of America, and filed February 9, 2000, of
which this application is a national stage filing
under 35 U.S.C. §371, was published under PCT Article
10 21(2) in English.

Foreign priority benefits are claimed under 35
U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of British
application number 9902919.1 filed February 9, 1999,
which designated at least one country other than the
15 United States.

The present invention is concerned with a
specific molecular mechanism by which inflammation and
susceptibility to infectious disease may be
genetically regulated, more specifically with a
20 molecular mechanism modulating the expression of
tumour necrosis factor- α (TNF- α). In particular, the
invention relates to two novel DNA binding proteins
which bind specifically to DNA target sites in the
TNF- α promoter region, to assays based on this
25 protein/DNA interaction and to a method of screening
for susceptibility to inflammatory disease based upon
screening for a polymorphism in the TNF- α promoter.

Background

30 Tumour necrosis factor- α is a pro-inflammatory
cytokine believed to play an important role in the
pathogenesis of many inflammatory and severe
infectious diseases. An example of a disease whose
severity is known to be associated with TNF- α is fatal
35 cerebral malaria which occurs in a small proportion of
individuals infected with the malaria parasite

- 1A -

Plasmodium falciparum. Clinical studies of cerebral malaria patients have demonstrated an association between host TNF- α levels and disease severity (Grau, G. E. et al. (1989) *New Engl. J. Med.* **320**: 1586-1591;
 5 Kwiatkowski, D. et al (1990) *Lancet* **336**: 1201-1204; Kern P. et al. (1989) *Am. J. Med.* **57**: 139-143) and experimental studies have revealed several ways in which excessive TNF- α production could promote cerebral malaria (Clark, I. A. (1987) *Parasitol. Today*
 10 **3**: 300-305; Grau, G. E. et al. (1987) *Science* **237**: 1210-1212).

In humans the gene for TNF- α resides within the class III region of the major histocompatibility complex (MHC) and several studies have shown that

it remains an open question as to whether the disease associations with polymorphisms in the TNF- α promoter region are due to a direct effect on the TNF- α gene regulation, as opposed to linkage disequilibrium with functional polymorphisms elsewhere in the TNF- α locus or neighbouring genes.

Summary

The present inventors have surprisingly found that one of the known polymorphisms in the TNF- α promoter region is located within a site of DNA/protein recognition and thus has a direct functional effect on TNF- α transcription via altered transcription factor recruitment. The present inventors have further identified two novel DNA binding proteins which specifically recognise DNA sites in the region of the TNF- α promoter surrounding this polymorphism.

Accordingly, in a first aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2.

Most preferably this protein, hereinafter referred to as the 21kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 21 +/-5kDa when run on an SDS PAGE denaturing gel.

In a second aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 3.

Most preferably this protein, referred to hereinafter as the 30kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 30kDa +/- 5kDa when run on an SDS PAGE denaturing gel.

- 3A -

The invention also provides isolated nucleic acids having the nucleotide sequences illustrated in

which are capable of specifically binding the above-described 21kDa DNA binding protein.

The invention also provides an isolated nucleic acid having the nucleotide sequence illustrated in SEQ ID NO: 3 a fragment thereof which is capable of binding specifically to the above-described 30kDa DNA binding protein.

The proteins of the invention are DNA binding proteins which have been characterised as binding specifically to DNA sequences within the promoter region of the TNF- α gene. As will be described in Example 2, the binding sites for these proteins were identified on the basis of solid phase DNAase I footprinting analysis of the region of the TNF- α promoter spanning positions -682 to -183 relative to the transcription start site using nuclear extracts from the cell line MonoMac6 which phenotypically resembles a well-differentiated human monocyte (Ziegler-Heitbrock, H.W.L. et al (1988) *Intl. J. Cancer* **41**: 456-461). The precise position of the protein binding sites has been further elucidated using electrophoretic mobility shift assays (EMSA) as will be described in detail in Example 3 below. Thus, the novel 21kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -391 to position -374 relative to the transcription start site, having the nucleotide sequence set forth in Figure 1a (SEQ ID NO: 1). This region, which includes the previously identified -376 G/A polymorphism, is hereinafter referred to as the α site. The novel 30kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -365 to position -352 relative to the transcription start site, having the nucleotide sequence set forth in Figure 2 (SEQ ID NO: 3). This region is hereinafter referred to as the

β site.

- 6 -

provides a sequence-specific DNA binding protein which is obtainable by

- (a) preparing a crude nuclear extract from the human monocyte cell line U937;
- 5 (b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;
- (c) applying a salt gradient from 100 to 2000mM to the column;
- 10 (d) collecting a fraction of the eluate which is enriched for the said sequence-specific DNA binding protein;
- (e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes
- 15 comprising the following sequence:

5'-GTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA (SEQ. ID NO: 4)
CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-5' (SEQ. ID NO: 8)

- 20 to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity probe; and

- (f) recovering the sequence-specific binding protein from the complexes formed in step (e). The
- 25 material eluted from the column by applying the salt gradient in step (c) may be divided into fractions and tested, for example using EMSA, in order to identify fraction(s) which are enriched for the 21kDa DNA binding protein. This material may then be used in
- 30 step (e).

Also provided is a sequence-specific DNA binding protein which is obtainable by:

- (a) preparing a crude nuclear extract from the human monocyte cell line U937;
- 35 (b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;

- 7 -

(c) applying a salt gradient from 100 to 2000mM to the column;

(d) collecting the material eluted at 250-350mM salt for heparin sepharose or 500-600mM salt for P11
5 phosphocellulose;

(e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes comprising the following sequence:

10 5'-TAGAAGGAAACAGACCACAGACCTG (SEQ. ID NO: 5)
ATCTTCCTTTGTCTGGTGTCTGGAC-5' (SEQ. ID NO: 9)

to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity
15 probe; and

(f) recovering the sequence-specific binding protein from the complexes formed in step (e).

The invention further provides oligonucleotide probes which are suitable for use in purifying the
20 21kDa and 30kDa DNA binding proteins on the basis of specific DNA-protein affinity binding. Thus the invention provides a nucleic acid molecule having the sequence of nucleotides illustrated in SEQ ID NO: 4 and a nucleic acid molecule having the sequence of
25 nucleotides illustrated in SEQ ID NO: 5. These nucleic acid molecules contain, respectively, specific binding sites for the 21kDa DNA binding protein and the 30kDa DNA binding protein.

The DNA molecules of the invention are preferably
30 double stranded and may be modified, for example by the addition of isotopic or non-isotopic labels. Also provided by the invention are materials comprising the above-described DNA molecules linked to a solid matrix or support. The solid matrix or support can be made
35 of a wide variety of materials in a wide variety of shapes, including for example microbeads and resin particles which may be packed into a chromatographic

interaction will result in an absence of the band corresponding to the complex in a similar manner to the competition experiments described in Example 3. The steps of "observing the presence or absence of complexes" might include simple qualitative detection of such complexes or quantitative measurement.

The invention also provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

10 contacting a DNA-protein complex comprising one of the following DNA/protein combinations:

- (i) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2 and the 21kDa DNA binding protein,
- 15 (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3 and the 30kDa DNA binding protein,
- (iii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2, the 21kDa DNA binding protein and the transcription factor protein Oct-1,
- 20

with a sample of the compound and observing whether the DNA-protein complex is disrupted following contact with the compound.

25 In a further aspect the invention provides a method of identifying a compound capable of modulating TNF- α gene expression, which method comprises contacting a fragment of DNA comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequences from the TNF- α promoter with a sample of the compound and detecting specific binding of the compound to the fragment of DNA.

35 The method of the invention is used to identify compounds capable of specifically binding to the α and β sites within the TNF- α promoter, which compounds may

- 12 -

thus be useful as modulators of the TNF- α transcription. Such compounds may be useful therapeutically in clinical situations in which it is desirable to up-regulate or down-regulate levels of
5 TNF- α .

In order to isolate compounds which interact specifically the α and/or the β site, the method of the invention uses α and β site sequences isolated from the remainder of the TNF- α promoter, i.e. in the
10 substantial absence of any other nucleotide sequences from the TNF- α promoter.

The readout of the assays of the invention may be provided by any technique known in the art to be useful in the detection of specific DNA/protein
15 binding. Preferably, the DNA fragments of interest are labelled, either with biochemical markers or radioisotopes and binding of compounds is screened by techniques such as, for example, electrophoretic mobility shift assay (EMSA). Alternatively, specific
20 binding interactions can be detected, without the need of labels, by proximity assay techniques such as, for example, flow cytometry or surface plasmon resonance. Advantageously, the assay method of the invention may be used to screen a combinatorial library of compounds
25 in order to identify any compounds capable of specifically binding to site α or site β .

In a still further aspect the invention provides a reporter gene expression construct comprising:

a reporter gene encoding a transcriptional and/or
30 translational product which can be directly or indirectly detected; and

a transcriptional control element comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the
35 substantial absence of any other nucleotide sequence from a TNF- α promoter, the transcriptional control element being operably linked to the reporter gene.

localisation of the α site in the TNF- α promoter
region. α_G (SEQ ID NO: 4) and α_A (SEQ ID NO: 26) probes
correspond to the nucleotide sequence extending from
position -407 to position -373

of the TNF- α promoter, with either a G or an A at position -376. Proximal α_G and α_A probes (SEQ ID NO: 28 and SEQ ID NO: 29) correspond to the nucleotide sequence extending from position -391 to position -373 of the TNF- α promoter, with either a G or an A at position -376. Distal α probe (SEQ ID NO: 27) corresponds to the sequence extending from position -407 to position -386 of the TNF- α promoter.

Figure 5 shows the results of an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the α site in the TNF- α promoter region. Nuclear extracts from unstimulated MonoMac6 cells were incubated with a radiolabelled α_G (lane 1), α_A (lane 4), distal α (lane 2), proximal α_G (lane 3) or proximal α_A (lane 5) probe.

Figure 6 shows an electrophoretic mobility shift assay (EMSA) investigating the binding of Oct-1 to the α site in the presence of an A substitution at position -376. Nuclear extracts from unstimulated MonoMac6 cells were incubated with a radiolabelled α_G (lanes 1 to 7) or α_A (lanes 8 to 14) probe either alone (lanes 1 and 8) or in the presence of anti-Oct-1 antibody (lanes 2 and 9), anti-p50 antibody (lanes 3 and 10) or unlabelled competitor probes (lanes 4 to 8 and 11 to 14).

Figure 7 shows the probes used in an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region (SEQ ID NO: 30). β corresponds to the sequence from nucleotide -372 to nucleotide -352 of the TNF- α promoter (SEQ ID NO: 5); β -1 corresponds to the sequence from nucleotide -365 to nucleotide -345 of the TNF- α promoter (SEQ ID NO: 31); β -2 corresponds to

the sequence from nucleotide -359 to nucleotide -339 of the TNF- α promoter (SEQ ID NO: 32).

Figure 8 shows the results of electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region. Nuclear extracts from LPS stimulated (lane 3) or unstimulated (lane 2 and 4-14) MonoMac6 cells were incubated with a radiolabelled β (lane 2, 3 and 11), β -1 (lane 13) or β -2 (lane 14) probe. A competition assay was also performed with a radiolabelled β probe in the presence of a 10x molar excess of an unlabelled β (lane 4), β -1 (lane 8), β -2 (lane 10) or EGR site F:agctAAATCCCCGCCCCGCGATGGA) (SEQ ID NO: 10) (lane 6) probe or in the presence of a 100x molar excess of unlabelled β (lane 5), β -1 (lane 9), β -2 (lane 11) or EGR site (lane 7) probe.

Figure 9 shows the results of UV-crosslinking experiments investigating proteins binding at the α and β sites of the TNF- α promoter. EMSA binding reactions were performed with radiolabelled double stranded oligonucleotide probes comprising the α site (with G or A at position -376, for complex I and II respectively) or the β site (complex III), in which five dT nucleotides were substituted with BrdU (as shown in Figure 10 below), complexes were crosslinked by UV light, excised and resolved using a 4-12% gradient polyacrylamide gel, either (a) directly or (b) after immunoprecipitation with anti-Oct-1 or control antibody.

Figure 10 shows the nucleotide sequence of the probes used in the cross-linking experiment described in Example 4. 5BrdU is shown as a Q.

Figure 11 is an EMSA using the β site specific probe (see below) illustrating the enrichment of proteins binding to site β of the TNF- α promoter using a P11

column: Lane 1 crude nuclear extract, lane 2 crude nuclear extract following incubation with P11, lane 3 low salt buffer wash of P11, lane 4 enriched material eluted from P11 with high salt buffer.

5

Figure 12 is an EMSA using the β site specific probe (see below) illustrating the purification of proteins which bind specifically to site β of the TNF- α promoter using DNA affinity purification: Lane 1 heparin sepharose enriched material, lane 2 bead-DNA purified material.

Detailed Description

Example 1 Preparation of Nuclear Extracts

15

MonoMac6 cells ($10\text{-}20 \times 10^6$) maintained in culture as previously described (Ziegler-Heitbrock, H. W. L. et al. *Int. J. Cancer*. **41**: 456-461 (1988)) were either harvested unstimulated or stimulated with 100ng/ml lipopolysaccharide (LPS) for 1 hour and then harvested. Nuclear extracts were prepared according to the method of Schrediber, E. et al. *Nucleic Acids Res.* **17**: 6419 (1989).

25 **Example 2 Solid Phase DNAase I Footprinting.**

Experimental method

Radiolabelled probes spanning the TNF- α promoter region from position -682 to position -183 relative to the transcription start site were generated by PCR using antisense primer 5'-GTTGGGGACACACAAGCATC (SEQ ID NO: 11) (end labelled with γ^{32} P-dATP using T4 polynucleotide kinase) and biotinylated primer 5'-GCATTATGAGTCTCCGGGTC (SEQ ID NO: 12) using TNFwt (-1173)-pXP1 plasmid DNA as template (construction of this plasmid is described in Example 5 part (A) below. The DNAase I footprinting procedure itself was carried

- 21A -

out according to the technique

b) Characterisation of complex II

The nature of complex II was further investigated by an EMSA supershift and competition assay, the results of which are shown in Figure 6. Complex II but not complex I was neutralised by the presence of antibody to Oct-1 (lanes 2 and 9) whilst neither complex was affected by anti-p50 (lanes 3 and 10). Complex I was competed by 100x molar excess of probe α_G (lane 4) or probe α_A (data not shown), both shown in Figure 4, but not by 100x molar excess of an oligoduplex probe matching an Oct-1 binding site from the human histone 2b gene (F:agctTCGCTTATGCAAATAAGGTGA) (SEQ ID NO: 13) (lanes 5 and 6) or a probe matching the EGR site (F:agctAAATCCCCGCCCGCGATGGA) (SEQ ID NO: 10) (lane 7). In contrast, complex II was competed by a molar excess of α_A (lane 11) and the probe matching the Oct-1 (lanes 12 and 13) but not by the probe matching the EGR site (lane 14) or probe α_G (data not shown). The EMSA supershift and competition data indicate that in the presence of TNF-_{376A} allele but not the presence of the TNF-_{376G} allele Oct-1 binds to the α site in addition to the 21kDa protein to form complex II.

25 c) Precise localisation of β site

In order to identify the precise region of the TNF- α promoter corresponding to the β site, an EMSA assay was carried out as described above, utilising the probes shown in Figure 7.

Figure 8 shows that formation of a complex (complex III) was observed with the β (lanes 2,3 and 12) and β -1 (lane 13) probes but not with the β -2 probe (lane 14). Furthermore, formation of complex III with the β probe was competed by a molar excess of the β (lanes 4 and 5) or the β -1 (lanes 8 and 9) probe but not by the

β -2 probe (lanes 10 and 11) or by an irrelevant probe (lanes 6 and 7).

These results, combined with those obtained from the Footprinting experiment of Example 2, suggest that the β site is localised between nucleotide -365 and -352 of the TNF- α promoter region.

Example 4 UV-crosslinking

Experimental methods

UV-crosslinking was carried out by first performing EMSA experiments using radiolabelled oligoduplex probes (SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38) in which specified dT nucleotides were substituted with BrdU, as shown in Figure 10. The EMSA gel was then illuminated with UV radiation at 302nm for 30 minutes at 4°C and exposed to autoradiography film for four hours at the same temperature. The autoradiography film was used to locate regions of the EMSA gel corresponding to the specific protein-DNA complexes. The relevant fragments of gel were then excised and the complexes eluted in 2x SDS buffer (100mM Tris-Cl pH 6.8, 200mM DTT, 2% SDS, 20% glycerol) at 37°C overnight. The complexes thus isolated were then resolved using a 4-12% gradient polyacrylamide gel either directly or after immunoprecipitation as previously described (Hansen, S.K. et al. *EMBO J.* **11**: 205-213).

Results

Figure 9 shows the results of UV-crosslinking experiments to investigate proteins binding at site α and β of the TNF- α promoter using α and β site oligoduplex probes. Figure 9(a) 4-12% gradient SDS-PAGE of complexes formed by incubation of crude

Table 1

	No Insert	376G	376A	P Value*
Basal	0.23±0.07	16.1±1.7	21.7±2.4	0.002
LPS-stimulated	0.25±0.1	189.9±19.3	200.3±13.7	ns
Ratio of LPS stimulated: basal	1.1±0.5	12.3±1.4	10.1±1.5	0.007

*P values shown for comparison of 376G and 376A constructs by two-tailed paired t-test. MonoMac6 cells were transfected with pXP1 vector containing no insert, which served as a negative control, or with one of two allelic forms of the TNF- α promoter region which differed by a single nucleotide substitution at position -376, either G (denoted as 376G) or A (denoted as 376A). The mean of 7 independent transi[s]ent transfection experiments is shown (\pm SEM) using two independent plasmid preparations. Cells were unstimulated to determine basal expression or stimulated with a high dose of LPS (200ng/ml). Luciferase activity of cell lysates was determined using a luminometer (with results corrected for total cell protein) and is expressed as luminometer units per mg protein.

Example 6 Clinical case-control studies.

(A) Study design

Children under 10 years of age were recruited to two independent case-control studies in the Gambia and Kenya. The Gambian study was carried out near Banjul and was hospital based as described previously (Hill, A.V.S. et al. (1991) *Nature* **352**: 595-600). In the Kenyan study cases of severe malaria recruited at the

nucleotide product spanning position -558 to position
-183 of the TNF- α promoter using 100ng of genomic DNA
as a template. This product was alkaline denatured
and hybridised in streptavidin coated microtitre
5 plates with allele-specific 5' biotinylated
oligonucleotide probes at 55°C for 2 hours. Allele-
specific capture probes used for TNF-238 were 5'-
CCTCGGAATCgGAGCAGGGA (SEQ ID NO: 14) and 5'-
CCTCGGAATCaGAGCAGGGA (SEQ ID NO: 15) at 2.5 pmol/ml;
10 for TNF-376 5'-CTGTCTGGAAgTTAGAAGGA (SEQ ID NO: 16) and
5'-CTGTCTGGAAaTTAGAAGGA (SEQ ID NO: 17) at 15 pmol/ml.
A split plate design was used for each polymorphism,
including positive and negative controls. Hybridised
DNA was labelled by incubation with 2mU anti-
15 digoxigenin peroxidase conjugate for 30 minutes at
37°C. After addition of 0.2mg of ABTS substrate
plates were read on an ELISA plate reader at 405nm
(reference filter 492nm). The accuracy of genotyping
data obtained by PCR ELISA was confirmed by DNA
20 sequencing.

Results

Results from the Gambian case control study are
25 summarised in Table 2 below:

Table 2

	Cerebral malaria	Severe malaria anaemia	Mild malaria	Non- malaria controls
TNF-376A				
<i>n</i>	384	132	349	371
Heterozygotes	24(6.3%)	5(3.8%)	13(3.7%)	9(2.4%)
Homozygotes	1(0.3%)	0	1(0.3%)	1(0.3%)

n number of individuals in each clinical category for
30 the Gambian case-control study. In a 2x2 analysis

site α

5'agctGTTCTATCTTTTTCTGCATCCTGTCTGGAAGTTA (SEQ ID NO: 18)

5'agctTAACTTCCAGACAGGATGCAGGAAAAAGATAGAAC (SEQ ID NO: 19)

site β

5'agctTAGAAGGAAACAGACCACAGACCTG (SEQ ID NO: 20)

5'agctCAGGTCTGTGGTCTGTTTCCTTCTA (SEQ ID NO: 21)

10

Crude nuclear extract prepared from unstimulated U937 cells will bind to heparin sepharose CL-6B (Pharmacia) and to phosphocellulose (P11) (Whatman) using BC100 buffer (20mM Hepes, 20% glycerol, 0.2mM EDTA and 100mM NaCl). The active material containing the protein(s) binding to site β are eluted by applying a salt gradient from 100 to 2000mM with enriched material eluted at 250-350mM (heparin sepharose) and 500-600mM (P11) BC buffer. Figure 11 illustrates this for P11 in an EMSA: lane 1 crude nuclear extract, lane 2 crude nuclear extract following incubation with P11 (demonstrating the protein is absent as it has bound to P11), lane 3 low salt buffer wash of P11 (demonstrating the protein remains bound to P11), lane 4 enriched material eluted from P11 with high salt buffer.

15

20

25

2) DNA affinity purification

Following heparin sepharose/P11 purification, the proteins binding to sites α and β are recovered by DNA affinity purification using site-specific oligonucleotide probes. The generic methodology for purification using biotinylated oligonucleotide probes linked to streptavidin coated beads has been described (Nucleic Acids Research 17, 6253-6267 (1989)). For site β the following biotinylated probe is

30

35

- 32A -

synthesised:

5'agctTAGAAGGAAACAGACCACAGACCTG (SEQ ID NO: 22)

ATCTTCCTTTGTCTGGTGTCTGGAC-biotin-5' (SEQ ID NO: 23)

For site α the following biotinylated probe is synthesised:

5'agctGTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA (SEQ ID NO:
5 24)
CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-biotin-5
(SEQ ID NO: 25)'

Procedures for the labelling of oligonucleotides
10 with biotin are well known in the art.

The appropriate double-stranded probe is added to streptavidin-coated DynabeadsJ (M-280) to which the probe becomes strongly bound. Incubation of the probe-bead complex with the enriched material
15 generated in part 1) allows binding of the proteins specific to the site of interest defined by the sequence of the oligonucleotide probe. Figure 12 shows the result of such a purification step for site β when the products are used in an EMSA (lane 1
20 heparin sepharose purified material, lane 2 bead-DNA purified material).

SEQUENCE LISTING

1. Sequence ID No. 1 corresponds to the nucleotide
25 sequence of the α site of the human TNF- α promoter illustrated in Figure 1a (TNF-_{376G} allele).
2. Sequence ID No. 2 corresponds to the nucleotide
30 sequence of the α site of the human TNF- α promoter illustrated in Figure 1b (TNF-_{376A} allele).
3. Sequence ID No. 3 corresponds to the nucleotide
35 sequence of the β site of the human TNF- α promoter illustrated in Figure 2.

- 33A -

4. Sequence ID No. 4 is the nucleotide sequence of

SEQUENCE LISTING

<110> KNIGHT, Julian Charles
KWIATKOWSKI, Dominic Peter

<120> MODULATOR OF INFLAMMATION

<130> I0317/7001 ERP/RE/CSM

<140> Not assigned yet

<141> 2001-08-07

<150> PCT/GB00/00414

<151> 2000-02-09

<160> 38

<170> PatentIn version 3.1

<210> 1

<211> 18

<212> DNA

<213> Homo sapiens

<400> 1
gcacccctgtc tgggaagtt

18

<210> 2

<211> 18

<212> DNA

<213> Homo sapiens

<400> 2

gcacccctgtc tggaaatt

18

<210> 3

<211> 14

<212> DNA

<213> Homo sapiens

<400> 3

acagaccaca gacc

14

<210> 4

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence:
 oligonucleotide containing binding site
 for the 21kDa DNA binding protein

<400> 4

gttctatctt tttcctgcat cctgtctgga agtta

35

<210> 5

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 30kDa DNA binding protein

<400> 5
tagaaggaaa cagaccacag acctg 25

<210> 6

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide probe for PCR ELISA

<400> 6
ctgtctggaa gttagaagga 20

<210> 7

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide probe for PCR ELISA

<400> 7
ctgtctggaa attagaagga 20

<210> 8

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 21kDa DNA binding protein

<400> 8

caagatagaa aaaggacgta ggacagacct tcaat

35

<210> 9

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: oligonucleotide containing binding site for the 30kDa DNA binding protein

<400> 9

atcttccttt gtctggtgac tggac

25

<210> 10

<211> 26

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: EGR site

<400> 10

agctaaatcc ccgccccgc gatgga

26

<210> 11

<211> 20

<223> Description of Artificial Sequence: Antisense primer

20

<220>

<223> Description of Artificial Sequence: Biotinylated primer

20

<220>

<223> Description of Artificial Sequence: Oligoduplex probe matching Oct-1 binding site from the human histone 2b gene

25

<210> 14

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 14

cctcgggaatc ggagcagggga

20

<210> 15

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 15

cctcgggaatc agagcagggga

20

<210> 16

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Allele-specific capture probe
used for TNF-238

<400> 16

ctgtctggaa gttagaagga

20

<210> 17
 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 <223> Description of Artificial Sequence: Allele-specific capture probe
 used for TNF-238

<400> 17
 ctgtctggaa attagaagga 20

<210> 18
 <211> 39
 <212> DNA
 <213> Artificial
 <220>
 <223> Description of Artificial Sequence: Probe designed to bind to alpha
 site

<400> 18
 agctgttcta tcttttttct gcattcctgtc tggaagtta 39

<210> 19
 <211> 39
 <212> DNA
 <213> Artificial
 <220>
 <223> Description of Artificial Sequence: Probe designed to bind to alpha
 site

<223> Description of Artificial Sequence: Beta site probe

29

<210> 23

<211> 25

<212> DNA

<213> Artificial

<220>

```
<221> misc_binding
```

<222> (25) .. (25)

<223> biotin

<220>

<223> Description of Artificial Sequence: Beta site probe

25

<210> 24

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Alpha site probe

39

<210> 25

<211> 35

<212> DNA

<213> Artificial

 $\langle 220 \rangle$

<223> Description of Artificial Sequence: Alpha site probe

<220>

```
<221> misc_binding
```

<222> (35) . . (35)

<223> biotin

```
<400> 25
caagatagaa aaaggacgta ggacagacct tcaat
```

35

<210> 26

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe alpha-A

```
<400> 26
gttctatctt tttcctgcat cctgtctgga aatta
```

35

<210> 27

<211> 22

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe distal alpha

22

<210> 28

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe proximal alpha-G

19

<210> 29

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Probe proximal alpha-A

19

<210> 30

<211> 36

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: TNF-alpha promoter region

<220>

<223> Description of Artificial Sequence: TNF-alpha promoter region probe

<400> 30
tagaaggaaa cagaccacag acctgggtccc caaaag 36

<210> 31

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: TNF-alpha promoter region probe

<400> 31
acagaccaca gacctgggtcc c 21

<210> 32

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: TNF-alpha promoter region probe

<400> 32

cacagacctg gtccccaaaa g

21

<210> 33

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-G

<220>

<221> modified_base

<222> (16)..(16)

<223> 5BrdU

<220>

<221> modified_base

<222> (20)..(20)

<223> 5BrdU

<220>

<221> modified_base

<222> (27)..(27)

<223> 5BrdU

<220>

<221> modified_base

<222> (31)..(31)

<223> 5BrdU

<220>

<221> modified_base

<222> (37)..(37)

<223> 5BrdU

<400> 33

agctgttcta tctttttcct gcacctgtc tggaagta

39

<210> 34

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site at pha-G

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe

<220>

<221> modified_base

<222> (5)..(5)

<223> 5BrdU

<220>

```
<221> modified_base
```

<222> (9) .. (10)

<223> 5BrdU

<220>

```
<221> modified_base
```

$\langle 222 \rangle \quad (21) \dots (21)$

<223> 5BrdU

<220>

```
<221> modified_base,
```

$\langle 222 \rangle \quad (34) \dots (34)$

<223> 5BrdU

<400> 34
agcttaactt ccagacagga tgcaggaaaa agatagaac

39

<210> 35

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-G

<223> Description of Artificial Sequence: UV-crosslinking probe site
alpha-A

<223> 5BrdU

<223> 5BrdU

<223> 5BrdU

<223> 5BrdU

```
<221> modified_base
```

$$\langle 222 \rangle \quad (10) \dots (10)$$

<223> 5BrdU

<220>

<221> modified_base

<222> (28)..(28)

<223> 5BrdU

<400> 37

agcttagaag gaaacagacc acagacctg

29

<210> 38

<211> 29

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: UV-crosslinking probe site beta

<220>

<221> modified_base

<222> (13)..(13)

<223> 5BrdU

<220>

<221> modified_base

<222> (16)..(16)

<223> 5BrdU

<220>

<221> modified_base

<222> (20)..(20)

<223> 5BrdU

<220>

<221> modified_base

<222> (22)..(22)

<223> 5BrdU

<220>

<221> modified_base

<222> (25)..(25)

<223> 5BrdU

<400> 38

agctcaggtc tgtggtctgt ttccttcta

MODULATOR OF INFLAMMATION

The present invention is concerned with a specific molecular mechanism by which inflammation and susceptibility to infectious disease may be genetically regulated, more specifically with a molecular mechanism modulating the expression of tumour necrosis factor- α (TNF- α). In particular, the invention relates to two novel DNA binding proteins which bind specifically to DNA target sites in the TNF- α promoter region, to assays based on this protein/DNA interaction and to a method of screening for susceptibility to inflammatory disease based upon screening for a polymorphism in the TNF- α promoter.

Tumour necrosis factor- α is a pro-inflammatory cytokine believed to play an important role in the pathogenesis of many inflammatory and severe infectious diseases. An example of a disease whose severity is known to be associated with TNF- α is fatal cerebral malaria which occurs in a small proportion of individuals infected with the malaria parasite *Plasmodium falciparum*. Clinical studies of cerebral malaria patients have demonstrated an association between host TNF- α levels and disease severity (Grau, G. E. et al. (1989) *New Engl. J. Med.* **320**: 1586-1591; Kwiatkowski, D. et al (1990) *Lancet* **336**: 1201-1204; Kern P. et al. (1989) *Am. J. Med.* **57**: 139-143) and experimental studies have revealed several ways in which excessive TNF- α production could promote cerebral malaria (Clark, I. A. (1987) *Parasitol. Today* **3**: 300-305; Grau, G. E. et al. (1987) *Science* **237**: 1210-1212).

In humans the gene for TNF- α resides within the class III region of the major histocompatibility complex (MHC) and several studies have shown that

- 2 -

individual variation in the level of TNF- α production can be linked to HLA type and to other polymorphic markers in the MHC class III region (Molving, J. et al. (1988) *Scand. J. Immunol.* **27**: 705-716; Jacob, C.O. et al. (1990) *Proc. Natl. Acad. Sci. USA* **87**: 1233-1237; Pociot, F. et al. (1993) *Eur. J. Immunol.* **23**: 224-231). These observations suggest that TNF- α responsiveness may be controlled by variable genetic elements in the MHC region but the precise location of these elements has yet to be identified.

In the search for genetic elements involved in the regulation of TNF- α gene expression there has been much interest in a group of single nucleotide polymorphisms located at positions -238, -308 and -376 relative to the TNF- α transcriptional start site. All three polymorphisms are substitutions of adenine for guanine, the allelic types being hereinafter denoted TNF_{-238G/-238A}, TNF_{-308G/-308A} and TNF_{-376G/-376A} respectively.

Population studies have shown that these polymorphisms in the TNF- α promoter may be associated with susceptibility to disease. For example, a study carried out in a population of Gambian children provided evidence that homozygotes for the TNF_{-308A} allele have an increased risk of developing cerebral malaria (McGuire, W. et al. (1994) *Nature* **371**: 508-511). The TNF_{-308A} allele has also been associated with susceptibility to a variety of other infectious diseases and chronic inflammatory diseases (Cabrera, M. et al. (1995) *J. Exp. Med.* **182**: 1259-1264; Conway, D.J. et al. (1997) *Infect. Immun.* **65**: 1003-1006; Nadel, S. et al. (1996) *J. Infect. Dis.* **174**: 878-880; Roy, S. et al. (1997) *J. Infect. Dis.* **176**: 530-532; Wilson, A. G. et al. (1994) *Eur. J. Immunol.* **24**: 191-195; Cox, A. et al. (1994) *Diabetologia* **37**: 500-503 and Louis, E. et al. (1996) *Gut* **39**: 705-710). However, at this time

- 3 -

it remains an open question as to whether the disease associations with polymorphisms in the TNF- α promoter region are due to a direct effect on the TNF- α gene regulation, as opposed to linkage disequilibrium with functional polymorphisms elsewhere in the TNF- α locus or neighbouring genes.

The present inventors have surprisingly found that one of the known polymorphisms in the TNF- α promoter region is located within a site of DNA/protein recognition and thus has a direct functional effect on TNF- α transcription via altered transcription factor recruitment. The present inventors have further identified two novel DNA binding proteins which specifically recognise DNA sites in the region of the TNF- α promoter surrounding this polymorphism.

Accordingly, in a first aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2.

Most preferably this protein, hereinafter referred to as the 21kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 21 +/-5kDa when run on an SDS PAGE denaturing gel.

In a second aspect the invention provides a sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 3.

Most preferably this protein, referred to hereinafter as the 30kDa protein, has an electrophoretic mobility equivalent to a protein of molecular weight 30kDa +/- 5kDa when run on an SDS PAGE denaturing gel.

The invention also provides isolated nucleic acids having the nucleotide sequences illustrated in

- 4 -

SEQ ID NO: 1 or SEQ ID NO: 2 or fragments thereof which are capable of specifically binding the above-described 21kDa DNA binding protein.

5 The invention also provides an isolated nucleic acid having the nucleotide sequence illustrated in SEQ ID NO: 3 a fragment thereof which is capable of binding specifically to the above-described 30kDa DNA binding protein.

10 The proteins of the invention are DNA binding proteins which have been characterised as binding specifically to DNA sequences within the promoter region of the TNF- α gene. As will be described in Example 2, the binding sites for these proteins were identified on the basis of solid phase DNAase I
15 footprinting analysis of the region of the TNF- α promoter spanning positions -682 to -183 relative to the transcription start site using nuclear extracts from the cell line MonoMac6 which phenotypically resembles a well-differentiated human monocyte
20 (Ziegler-Heitbrock, H.W.L. et al (1988) *Intl. J. Cancer* **41**: 456-461). The precise position of the protein binding sites has been further elucidated using electrophoretic mobility shift assays (EMSA) as will be described in detail in Example 3 below. Thus,
25 the novel 21kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -391 to position -374 relative to the transcription start site, having the nucleotide sequence set forth in Figure 1a. This region, which
30 includes the previously identified -376 G/A polymorphism, is hereinafter referred to as the α site. The novel 30kDa DNA binding protein has been shown to bind to a site in the region of the TNF- α promoter extending from position -365 to position
35 -352 relative to the transcription start site, having the nucleotide sequence set forth in Figure 2. This region is hereinafter referred to as the β site.

- 5 -

Complexes of the proteins of the invention bound to synthetic oligonucleotides comprising the sequence of the α and β sites have been isolated using UV-crosslinking experiments and the molecular weight of the proteins has been determined using SDS-PAGE, as
5 will be described in detail in Example 4.

The sequence-specific DNA binding properties of the 21kDa and 30kDa proteins can be readily exploited to purify the proteins on the basis of their binding
10 specificity using techniques already known to those skilled in the art of protein purification. For example, the proteins may be purified from crude cell extracts (such as the nuclear extract of MonoMac6 cells or U937 cells described herein) on the basis of
15 binding affinity by passing the nuclear extract over a solid support, such as a column matrix, to which have been attached synthetic oligonucleotides comprising a sequence corresponding to site α or site β . The desired proteins, bound to the matrix, may then be
20 released by using appropriate buffers, known in the art, and further purified by biochemical procedures such as, for example, SDS-PAGE electrophoresis or Reverse-Phase High Pressure Liquid Chromatography (RP-HPLC).

Partial amino acid sequences of the purified proteins may be determined using methods known to those skilled in the art of protein sequencing. For example, the purified molecule may be subjected to an
25 Edman degradation reaction or, alternatively, to tandem mass-spectrometry. Prior to undertaking these procedures, it may be advantageous to cleave the purified molecule into smaller peptide fragments, for example, by using a protein cleaving enzyme such as
30 trypsin followed by separation of the different fragments by Reverse-Phase High Pressure Liquid Chromatography (RP-HPLC).
35

Thus, in a still further aspect the invention

- 6 -

provides a sequence-specific DNA binding protein which is obtainable by

(a) preparing a crude nuclear extract from the human monocyte cell line U937;

5 (b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;

(c) applying a salt gradient from 100 to 2000mM to the column;

10 (d) collecting a fraction of the eluate which is enriched for the said sequence-specific DNA binding protein;

(e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes
15 comprising the following sequence:

5'-GTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA
CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-5'

20 to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity probe; and

(f) recovering the sequence-specific binding protein from the complexes formed in step (e). The
25 material eluted from the column by applying the salt gradient in step (c) may be divided into fractions and tested, for example using EMSA, in order to identify fraction(s) which are enriched for the 21kDa DNA binding protein. This material may then be used in
30 step (e).

Also provided is a sequence-specific DNA binding protein which is obtainable by:

(a) preparing a crude nuclear extract from the human monocyte cell line U937;

35 (b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;

- 7 -

(c) applying a salt gradient from 100 to 2000mM to the column;

(d) collecting the material eluted at 250-350mM salt for heparin sepharose or 500-600mM salt for P11 phosphocellulose;

(e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes comprising the following sequence:

10 5'-TAGAAGGAAACAGACCACAGACCTG
 ATCTTCCTTTGTCTGGTGTCTGGAC-5'

to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity probe; and

(f) recovering the sequence-specific binding protein from the complexes formed in step (e).

The invention further provides oligonucleotide probes which are suitable for use in purifying the 21kDa and 30kDa DNA binding proteins on the basis of specific DNA-protein affinity binding. Thus the invention provides a nucleic acid molecule having the sequence of nucleotides illustrated in SEQ ID NO: 4 and a nucleic acid molecule having the sequence of nucleotides illustrated in SEQ ID NO: 5. These nucleic acid molecules contain, respectively, specific binding sites for the 21kDa DNA binding protein and the 30kDa DNA binding protein.

The DNA molecules of the invention are preferably double stranded and may be modified, for example by the addition of isotopic or non-isotopic labels. Also provided by the invention are materials comprising the above-described DNA molecules linked to a solid matrix or support. The solid matrix or support can be made of a wide variety of materials in a wide variety of shapes, including for example microbeads and resin particles which may be packed into a chromatographic

- 8 -

column. Such material is particularly useful in the purification of the 21kDa or 30kDa DNA binding proteins by DNA affinity binding. The material is first incubated with a mixture containing the DNA binding protein, such as a crude or semi-purified nuclear extract, under conditions which allow for specific DNA-protein binding. The use of a solid matrix or support then facilitates the separation of the desired DNA-protein complexes from unbound components of the crude mixture. In a preferred embodiment, exemplified herein, the DNA molecule is labelled with biotin and is attached to solid microbeads (e.g. magnetic Dynabeads™) via a biotin-streptavidin binding interaction.

The two regions of the TNF- α promoter denoted herein site α and site β have been identified as protein binding sites on the basis of DNAase I footprinting and EMSA experiments and are therefore putative *cis*-acting regulatory elements within the TNF- α promoter. Of the three previously described polymorphisms in the TNF- α promoter only one, the -376 G/A polymorphism, occurs within one of the putative *cis*-acting regulatory elements. As will be described in detail in Example 5, the present inventors were able to demonstrate that the -376 G/A substitution has a direct effect on TNF- α transcription by placing a 1.2kb fragment of the human TNF- α promoter upstream of a luciferase reporter gene and transiently expressing the construct in MonoMac6 cells. The -376 G/A polymorphism was introduced into the reporter gene construct by site-directed mutagenesis. Constructs containing the A substitution (-376A) showed a 35% increase in basal reporter gene expression compared to the wild-type promoter (-376G).

The present inventors have further demonstrated that the pattern of protein binding to site α is markedly altered by the naturally occurring

- 9 -

polymorphism at position -376. As will be described in detail in Examples 3 and 4, both EMA and UV-crosslinking experiments demonstrated that whilst the 21kDa DNA binding protein is able to bind to the α site of both the TNF_{-376A} and TNF_{-376G} alleles, in the presence of the TNF_{-376A} allele but not the TNF_{-376G} allele a second protein of molecular weight of 95kDa (hereinafter referred to as the 95kDa protein) can bind to the α site in addition to the 21kDa protein.

Thus, sites α and β of the TNF- α promoter normally interact with the 21kDa and 30kDa proteins respectively and the TNF_{-376A} allele serves to recruit a third protein of about 95 kDa to the α site. The present inventors have further demonstrated with the use of EMSA supershift and competition experiments that the 95kDa protein is the ubiquitously expressed transcription factor Oct-1 (Fletcher *et al.*, Cell, 51: 773-781, 1987; Herr *et al.*, Genes Dev, 9: 1679, 1995).

Knowledge of the specific DNA-protein binding interactions important in the regulation of TNF- α transcription can be used to design assays to identify compounds capable of disrupting the DNA-protein binding interactions and thus modulating TNF- α transcription. Compounds thus identified may be useful therapeutically in clinical situations in which it is desirable to up-regulate or down-regulate the level of TNF- α expression.

Accordingly, in a further aspect the invention provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises the steps of:

- (a) contacting an aqueous solution comprising the 21kDa binding protein with a sample of the compound to form a reaction mixture;
- (b) contacting the reaction mixture of part (a) with a DNA fragment comprising the nucleotide sequence illustrated in SEQ ID NO: 1 or SEQ ID NO: 2;

- 10 -

(c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

In a further aspect the invention provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

(a) contacting an aqueous solution comprising the 21kDa DNA binding protein and the transcription factor protein Oct-1 with a sample of the compound to form a reaction mixture;

(b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2;

(c) observing the presence or absence of complexes comprising said DNA fragment.

The invention further provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

(a) contacting an aqueous solution comprising the 30kDa DNA binding protein with a sample of the compound to form a reaction mixture;

(b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3.

(c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

The above methods of the invention can advantageously be performed in the form of an electrophoretic mobility shift assay (EMSA), as described in Example 3 below. A sample of the compound to be tested may be added to the reaction mixture prior to the addition of radiolabelled probe.

Binding reactions with and without the test compound are then analysed by electrophoresis. Compounds capable of disrupting the specific DNA-protein binding

- 11 -

interaction will result in an absence of the band corresponding to the complex in a similar manner to the competition experiments described in Example 3. The steps of 'observing the presence or absence of complexes' might include simple qualitative detection of such complexes or quantitative measurement.

The invention also provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

contacting a DNA-protein complex comprising one of the following DNA/protein combinations:

- (i) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2 and the 21kDa DNA binding protein,
- (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3 and the 30kDa DNA binding protein,
- (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2, the 21kDa DNA binding protein and the transcription factor protein Oct-1,

with a sample of the compound and observing whether the DNA-protein complex is disrupted following contact with the compound.

In a further aspect the invention provides a method of identifying a compound capable of modulating TNF- α gene expression, which method comprises contacting a fragment of DNA comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequences from the TNF- α promoter with a sample of the compound and detecting specific binding of the compound to the fragment of DNA.

The method of the invention is used to identify compounds capable of specifically binding to the α and β sites within the TNF- α promoter, which compounds may

- 12 -

thus be useful as modulators of the TNF- α transcription. Such compounds may be useful therapeutically in clinical situations in which it is desirable to up-regulate or down-regulate levels of TNF- α .

In order to isolate compounds which interact specifically the α and/or the β site, the method of the invention uses α and β site sequences isolated from the remainder of the TNF- α promoter, i.e. in the substantial absence of any other nucleotide sequences from the TNF- α promoter.

The readout of the assays of the invention may be provided by any technique known in the art to be useful in the detection of specific DNA/protein binding. Preferably, the DNA fragments of interest are labelled, either with biochemical markers or radioisotopes and binding of compounds is screened by techniques such as, for example, electrophoretic mobility shift assay (EMSA). Alternatively, specific binding interactions can be detected, without the need of labels, by proximity assay techniques such as, for example, flow cytometry or surface plasmon resonance. Advantageously, the assay method of the invention may be used to screen a combinatorial library of compounds in order to identify any compounds capable of specifically binding to site α or site β .

In a still further aspect the invention provides a reporter gene expression construct comprising:

a reporter gene encoding a transcriptional and/or transnational product which can be directly or indirectly detected; and

a transcriptional control element comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequence from a TNF- α promoter, the transcriptional control element being operably linked to the reporter gene.

- 13 -

As used herein the term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. In this case, the
5 transcriptional control element functions to drive transcription of the reporter gene.

Reporter genes suitable for use in the expression construct might include, for example, chloramphenicol acetyltransferase (CAT), β -galactosidase, firefly
10 luciferase and green fluorescent protein. Following transfection into a host cell, reporter gene expression from the construct can be monitored either by direct measurement of mRNA or protein or by indirect measurement of properties of the protein such
15 as enzymatic activity or fluorescence.

A suitable plasmid based reporter gene expression construct would include a reporter gene DNA with a downstream polyadenylation signal, an upstream multiple cloning site into which the transcriptional
20 control element can be inserted, a synthetic polyadenylation signal upstream of the multiple cloning site to prevent read-through transcription from spurious promoter sequences in the vector backbone, a bacterial origin of replication and
25 bacterial antibiotic resistance gene(s) to allow manipulation of the plasmid in a bacterial host strain. Suitable reporter gene expression vectors into which putative *cis*-acting regulatory elements of interest can be easily inserted are commercially
30 available (for example from Promega, Madison, WI USA). The expression construct may advantageously contain further *cis*-acting promoter elements from a heterologous RNA polymerase II dependent promoter which function to increase the basal level of reporter
35 gene expression.

The invention further provides cells which have been transfected with the expression constructs of the

- 14 -

invention and still further provides a method of identifying compounds capable of modulating TNF- α gene expression, which method comprises comparing the amount of reporter gene expression in these cells in the presence of the compound with the amount of reporter gene expression in the absence of the compound or with the amount of reporter gene expression in cells transfected with a control reporter gene expression construct which does not contain the α and β sites of the TNF- α promoter, whereby compounds capable of modulating TNF- α gene expression are identified.

In order to isolate compounds which interact specifically the α and/or the β site, the reporter gene expression construct should preferably contain the α and β site sequences isolated from the remainder of the TNF- α promoter, i.e. in the substantial absence of any other nucleotide sequences from the TNF- α promoter.

The method of the invention preferably uses cells which have been stably transfected to provide a cell line in which the reporter gene construct is stably integrated at a chromosomal location. To facilitate the production of stable cell lines one of the known eukaryotic selectable markers may be added to the reporter gene expression construct. Following transfection, stable lines may be selected and propagated by culturing in media containing the appropriate selective agent.

In contrast to the assay methods described above, which detect specific binding of compounds to the α and β sites of the TNF- α promoter using physical techniques, the assay method based upon the use of cells transfected with reporter gene constructs containing the α and β sites, uses a biological assay readout based on altered transcription. The assay may

- 15 -

be used to identify compounds capable of modulating TNF- α expression which may be useful therapeutically in clinical situations in which it is desirable to up-regulate or down-regulate levels of TNF- α .

5 In a still further aspect the invention provides a method of screening human individuals for predisposition to inflammatory disease, which method comprises screening for the presence of a G to A transition polymorphism at position -376 in the
10 promoter region of the TNF- α gene.

Having identified that the -376 G/A polymorphism has a direct functional effect on TNF- α transcription *in vitro*, the present inventors performed a study to address the question of whether the -376 G/A
15 polymorphism also exerts a functional effect on TNF- α regulation *in vivo* by examining the association between the polymorphism and susceptibility to cerebral malaria in two distinct African populations. As previously mentioned, clinical studies on cerebral
20 malaria patients have demonstrated an association between host TNF- α levels and disease severity.

In the first part of this study the inventors analysed DNA samples from a large case control study of severe malaria in Gambian children. As will be
25 described in detail in Example 6 the Gambian study identified TNF-_{-376A} as an independent determinant of cerebral malaria with an estimated odds ratio of 4.3 when compared to a control group (95% confidence interval 1.5-12.8, P=0.008). On the basis of the
30 Gambian study the inventors formulated the hypothesis that the TNF-_{-376A} allele is a determinant of susceptibility to cerebral malaria. In order to test this hypothesis the inventors examined the frequency of the TNF-_{-376A} allele in an independent case control
35 study of severe malaria in Kenyan children. In the Kenyan study population the TNF-₋₃₇₆ allele was found to be in strong linkage disequilibrium with the TNF-_{-238A}

- 16 -

allele ($\Delta = 8.35$ $P < 0.001$). Logistic regression analysis of the two linked polymorphisms, combined with ethnic group, indicated that possession of the TNF_{-376A} allele was associated with increased susceptibility to cerebral malaria (cerebral malaria cases vs controls: OR 5.0, 95% CI 1.5-17.0, $P = 0.010$) while possession of the TNF_{-238A} allele was associated with protection (OR 0.2, 95% CI 0.08-0.7, $P = 0.008$). The present inventors have thus identified a strong relationship between the TNF_{-376A} allele and susceptibility to cerebral malaria in two populations with widely divergent genetic features living on opposite sites of the African continent.

Cerebral malaria is just one example of an inflammatory disease in which TNF- α is known to play an important role. Given that the -376 G/A polymorphism has been shown by the present inventors to have a direct functional effect on the basal level of TNF- α transcription there is a reasonable expectation that the TNF_{-376A} allele is also associated with susceptibility to other inflammatory diseases in which TNF- α is known to be an important factor such as, for example, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus and the like. Accordingly, the method of the invention may be used to screen for susceptibility to any inflammatory disease in which TNF- α is known to be important. The method of the invention is particularly useful in screening for susceptibility to cerebral malaria.

The method of the invention involves determining the genotype of an individual at the -376 position of the TNF- α promoter (also referred to herein as 'genotyping') to establish whether the individual carries TNF_{-376A} or TNF_{-376G} alleles. The method may comprise screening for the presence or absence in the genome of the subject of both the TNF_{-376A} allele and the TNF_{-376G} allele or may comprise screening for the

- 17 -

presence or absence of either individual allele, it generally being possible to draw conclusions about the genotype of an individual at a biallelic polymorphic locus just by screening for one or other of the variant alleles.

Genotyping may be carried out according to any of the techniques known to those skilled in the art of genetic screening. For example, genotyping may be accomplished with the method used by the present inventors in Example 6 part (b), namely PCR ELISA on samples of genomic DNA using differential hybridisation with allele specific oligonucleotide probes. The following oligonucleotide sequences are preferred for use as allele specific probes:

5'-CTGTCTGGAAgTTAGAAGGA (TNF_{-376G} allele, SEQ ID NO:6)
5'-CTGTCTGGAAaTTAGAAGGA (TNF_{-376A} allele, SEQ ID NO:7)

Alternative techniques which can be used to perform genotyping at the TNF₋₃₇₆ locus in accordance with the invention might include mass spectrometry, particularly matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, see Roskey, M. T. et.al., 1996, PNAS USA, 93: 4724-4729), single nucleotide primer extension (Shumaker, J. M. et.al., 1996, Hum. Mutat., 7: 346-354; Pastinen, T. et.al., 1997, Genome Res., 7: 606-614) and DNA chips or microarrays (Underhill, P. A. et.al., 1996, PNAS USA, 93: 196-200; Gilles, P. N. et.al. Nat. Biotech., 1999, 17: 365-370). In addition to the above, SNPs are commonly scored using PCR-based techniques, such as PCR-SSP using allele-specific primers (described by Bunce, 1995). Techniques for the scoring of DNA polymorphisms are reviewed by Schafer, A. J. and Hawkins, J. R. in Nature Biotechnology, Vol 16, pp33-39 (1998).

As would be readily apparent to those skilled in

- 18 -

the art, genotyping is generally carried out on genomic DNA prepared from a suitable tissue sample obtained from the subject under test. Most commonly, genomic DNA is prepared from a sample of whole blood, according to standard procedures which are well known in the art.

The present invention may be further understood with reference to the following Examples together with the accompanying Figures in which:

10

Figure 1 shows the nucleotide sequence of the TNF- α promoter from position -391 to position -374 relative to the transcription start site, corresponding to the α site; 1a is the wild type TNF_{-376G} allele, 1b is the polymorphic variant TNF_{-376A} allele.

15

Figure 2 shows the nucleotide sequence of the TNF- α promoter from position -365 to position -352 relative to the transcription start site, corresponding to the β site.

20

Figure 3 shows the results of a solid phase DNAase I footprinting experiment using a radiolabelled probe spanning the region from position -682 to position -183 of the TNF- α promoter, in the absence of nuclear extract (lanes 2 and 5) or incubated with nuclear extracts prepared from unstimulated MonoMac6 cells (lane 3) or MonoMac6 cells stimulated with lipopolysaccharide (LPS) (lane 4). Lane 1 is the Maxam Gilbert sequencing ladder for the same region of the TNF- α promoter.

25

30

Figure 4 shows the probes used in an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the α site in the TNF- α promoter region. α_G and α_A probes correspond to the nucleotide sequence extending from position -407 to position -373

35

- 19 -

of the TNF- α promoter, with either a G or an A at position -376. Proximal α_G and α_A probes correspond to the nucleotide sequence extending from position -391 to position -373 of the TNF- α promoter, with either a G or an A at position -376. Distal α probe corresponds to the sequence extending from position -407 to position -386 of the TNF- α promoter.

Figure 5 shows the results of an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the α site in the TNF- α promoter region. Nuclear extracts from unstimulated MonoMac6 cells were incubated with a radiolabelled α_G (lane 1), α_A (lane 4), distal α (lane 2), proximal α_G (lane 3) or proximal α_A (lane 5) probe.

Figure 6 shows an electrophoretic mobility shift assay (EMSA) investigating the binding of Oct-1 to the α site in the presence of an A substitution at position -376. Nuclear extracts from unstimulated MonoMac6 cells were incubated with a radiolabelled α_G (lanes 1 to 7) or α_A (lanes 8 to 14) probe either alone (lanes 1 and 8) or in the presence of anti-Oct-1 antibody (lanes 2 and 9), anti-p50 antibody (lanes 3 and 10) or unlabelled competitor probes (lanes 4 to 8 and 11 to 14).

Figure 7 shows the probes used in an electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region. β corresponds to the sequence from nucleotide -372 to nucleotide -352 of the TNF- α promoter; β -1 corresponds to the sequence from nucleotide -365 to nucleotide -345 of the TNF- α promoter; β -2 corresponds to the sequence from nucleotide -359 to nucleotide -339 of the TNF- α promoter.

- 20 -

Figure 8 shows the results of electrophoretic mobility shift assay (EMSA) investigating the precise localisation of the β site in the TNF- α promoter region. Nuclear extracts from LPS stimulated (lane 3) or unstimulated (lane 2 and 4-14) MonoMac6 cells were incubated with a radiolabelled β (lane 2, 3 and 11), β -1 (lane 13) or β -2 (lane 14) probe. A competition assay was also performed with a radiolabelled β probe in the presence of a 10x molar excess of an unlabelled β (lane 4), β -1 (lane 8), β -2 (lane 10) or EGR site (F:agctAAATCCCCGCCCCGCGATGGA) (lane 6) probe or in the presence of a 100x molar excess of unlabelled β (lane 5), β -1 (lane 9), β -2 (lane 11) or EGR site (lane 7) probe.

Figure 9 shows the results of UV-crosslinking experiments investigating proteins binding at the α and β sites of the TNF- α promoter. EMSA binding reactions were performed with radiolabelled double stranded oligonucleotide probes comprising the α site (with G or A at position -376, for complex I and II respectively) or the β site (complex III), in which five dT nucleotides were substituted with BrdU (as shown in Figure 10 below), complexes were crosslinked by UV light, excised and resolved using a 4-12% gradient polyacrylamide gel, either (a) directly or (b) after immunoprecipitation with anti-Oct-1 or control antibody.

Figure 10 shows the nucleotide sequence of the probes used in the cross-linking experiment described in Example 4. 5BrdU is shown as a Q.

Figure 11 is an EMSA using the β site specific probe (see below) illustrating the enrichment of proteins binding to site β of the TNF- α promoter using a P11

- 21 -

column: Lane 1 crude nuclear extract, lane 2 crude nuclear extract following incubation with P11, lane 3 low salt buffer wash of P11, lane 4 enriched material eluted from P11 with high salt buffer.

5

Figure 12 is an EMSA using the β site specific probe (see below) illustrating the purification of proteins which bind specifically to site β of the TNF- α promoter using DNA affinity purification: Lane 1
10 heparin sepharose enriched material, lane 2 bead-DNA purified material.

Example 1 Preparation of Nuclear Extracts

15 MonoMac6 cells ($10\text{--}20 \times 10^6$) maintained in culture as previously described (Ziegler-Heitbrock, H. W. L. et al. *Int. J. Cancer*. **41**: 456-461 (1988)) were either harvested unstimulated or stimulated with 100ng/ml lipopolysaccharide (LPS) for 1 hour and then
20 harvested. Nuclear extracts were prepared according to the method of Schrediber, E. et al. *Nucleic Acids Res.* **17**: 6419 (1989).

Example 2 Solid Phase DNAase I Footprinting.

Experimental method

Radiolabelled probes spanning the TNF- α promoter region from position -682 to position -183 relative to the transcription start site were generated by PCR
30 using antisense primer 5'-GTTGGGGACACACAAGCATC (end labelled with $\gamma^{32}\text{P}$ -dATP using T4 polynucleotide kinase) and biotinylated primer 5'-GCATTATGAGTCTCCGGGTC using TNFwt (-1173)-pXP1 plasmid DNA as template (construction of this plasmid is described in Example
35 5 part (A) below. The DNAase I footprinting procedure itself was carried out according to the technique

- 22 -

described by Sandaltzopoulos and Becker (*Nucleic Acids Research*. **22**: 1511-1515 (1994)). Briefly, the DNA-binding reactions comprised radiolabelled DNA probe (40,000 cpm) absorbed onto magnetic Dynabeads™ M-280-Streptavidin (DYNAL, Norway) in binding reaction buffer (12mM HEPES, pH 7.8, 80-100mM KCl, 1mM EDTA, 12% glycerol and poly (dI-dC)) either alone (naked DNA) or incubated with 20µg crude nuclear extract prepared from MonoMac6 cells according to Example 1. The products of the DNA-binding reactions were subjected to DNAase I digestion 0.12-0.25U for 30 seconds, washed and analysed on a 7% acrylamide 7M urea gel. Areas of protection were localised by comparasion with a Maxam-Gilbert sequencing ladder.

Results

Figure 3 shows that two novel sites of DNA-protein interaction are seen with nuclear extracts from LPS stimulated and unstimulated MonoMac6 cells. The first, designated α , is located between position -404 and position - 374 of the TNF- α promoter region. The second, designated β , is located between position -371 and position -352. A further region of protection at position -600 is seen with nuclear extracts from LPS stimulated cells only and corresponds to the previously known NF- κ B site cluster.

Example 3 Electrophoretic Mobility Shift Assay.

Experimental method

Double stranded oligonucleotide probes were annealed and radiolabelled with an equimolar amount of α^{32} P-dCTP using DNA polymerase I. Binding reactions were assembled containing 1µg crude nuclear extract prepared according to Example 1 and 4000 cpm

- 23 -

radiolabelled probe in 10mM HEPES (pH 7.8), 50mM KCl, 1mM EDTA, 1mM EGTA, 12.5% glycerol, 1 μ g poly(dI-dC) (Amersham Pharmacia Biotech) and incubated for 20 minutes at room temperature. The binding reactions were analysed by electrophoresis in a non-denaturing 5% polyacrylamide gel at 4°C in 0.5% TBE buffer. EMSA supershift analysis was performed by pre-incubation of the reaction mixture with an appropriate antiserum (Santa Cruz) at room temperature for 10 minutes prior to addition of the radiolabelled probe.

Results

a) Precise localisation of α site

In order to identify the precise region of the TNF- α promoter corresponding to the α site, and EMSA assay was carried out as described above, incubating the different probes shown in Figure 4 with nuclear extracts from unstimulated MonoMac cells. Figure 5 shows that a low molecular weight complex (complex I) was observed with the α_G (lane 1) and α_A (lane 4) probes, as well as with the proximal α_G (lane 3) and α_A (lane 5) probes. An additional high molecular weight complex (complex II) was observed only with the α_A (lane 4) and proximal α_A (lane 5) probes, indicating that the G/A polymorphism at position -376 has a direct effect on recruitment of DNA-binding proteins at the α site. No complex was observed with the distal α probe (lane 2), showing that the 5' region of α_G or α_A is not involved in any DNA-protein interaction. These data, combined with those obtained from the Footprinting experiment of Example 2, suggest that the α site is localised between nucleotide -391 and nucleotide -374 of the TNF- α promoter.

35

- 24 -

b) Characterisation of complex II

The nature of complex II was further investigated by an EMSA supershift and competition assay, the results of which are shown in Figure 6. Complex II but not complex I was neutralised by the presence of antibody to Oct-1 (lanes 2 and 9) whilst neither complex was affected by anti-p50 (lanes 3 and 10). Complex I was competed by 100x molar excess of probe α_G (lane 4) or probe α_A (data not shown), both shown in Figure 4, but not by 100x molar excess of an oligoduplex probe matching an Oct-1 binding site from the human histone 2b gene (F:agctTCGCTTATGCAAATAAGGTGA) (lanes 5 and 6) or a probe matching the EGR site (F:agctAAATCCCCGCCCCGCGATGGA) (lane 7). In contrast, complex II was competed by a molar excess of α_A (lane 11) and the probe matching the Oct-1 (lanes 12 and 13) but not by the probe matching the EGR site (lane 14) or probe α_G (data not shown). The EMSA supershift and competition data indicate that in the presence of TNF-_{376A} allele but not the presence of the TNF-_{376G} allele Oct-1 binds to the α site in addition to the 21kDa protein to form complex II.

c) Precise localisation of β site

In order to identify the precise region of the TNF- α promoter corresponding to the β site, an EMSA assay was carried out as described above, utilising the probes shown in Figure 7. Figure 8 shows that formation of a complex (complex III) was observed with the β (lanes 2,3 and 12) and β -1 (lane 13) probes but not with the β -2 probe (lane 14). Furthermore, formation of complex III with the β probe was competed by a molar excess of the β (lanes 4 and 5) or the β -1 (lanes 8 and 9) probe but not by the

- 25 -

β -2 probe (lanes 10 and 11) or by an irrelevant probe (lanes 6 and 7).

These results, combined with those obtained from the Footprinting experiment of Example 2, suggest that the β site is localised between nucleotide -365 and -352 of the TNF- α promoter region.

Example 4 UV-crosslinking

Experimental methods

UV-crosslinking was carried out by first performing EMSA experiments using radiolabelled oligoduplex probes in which specified dT nucleotides were substituted with BrdU, as shown in Figure 10. The EMSA gel was then illuminated with UV radiation at 302nm for 30 minutes at 4°C and exposed to autoradiography film for four hours at the same temperature. The autoradiography film was used to locate regions of the EMSA gel corresponding to the specific protein-DNA complexes. The relevant fragments of gel were then excised and the complexes eluted in 2x SDS buffer (100mM Tris-Cl pH 6.8, 200mM DTT, 2% SDS, 20% glycerol) at 37°C overnight. The complexes thus isolated were then resolved using a 4-12% gradient polyacrylamide gel either directly or after immunoprecipitation as previously described (Hansen, S.K. et al. *EMBO J.* **11**: 205-213).

Results

Figure 9 shows the results of UV-crosslinking experiments to investigate proteins binding at site α and β of the TNF- α promoter using α and β site oligoduplex probes. Figure 9(a) 4-12% gradient SDS-PAGE of complexes formed by incubation of crude

- 26 -

nuclear extracts from unstimulated MonoMac6 cells with α site probes containing A (lane 1) or G (lane 2) at position -376 or with β site probes (lane 3), all shown in Figure 10. The molecular weights of the complexes were determined by comparing their electrophoretic mobility with that of molecular weight markers. The molecular weights of the proteins binding to site α or β were then calculated by subtracting the molecular weight of the oligonucleotide probes. Two proteins of about 21kDa and 30kDa were shown to bind to the α and β sites, respectively. Furthermore, another protein of about 95kDa was shown to bind, together with the 21kDa protein, only to the α_A site but not to the α_C site. The estimates of molecular weight are accurate only to ± 5 kDa, since the migration of the complexes may be influenced by various structural variables. Figure 9(b) shows SDS-PAGE after immunoprecipitation of complexes I and II with anti-Oct-1 or a control unrelated antibody (anti-p50 NF- κ B). UV crosslinked forms of complex II but not of complex I could be specifically immunoprecipitated by anti-Oct-1 antibodies, showing that the protein of about 95kDa is Oct-1. Both Figure 9(a) and 9(b) show that the binding of Oct-1 is specific for the TNF_{-376A} allele.

Example 5 Reporter gene analysis

(a) Plasmid construction

The plasmid TNFwt (-1173)-pXP1 was constructed by placing a ~1.2kb fragment of the wild type TNF- α promoter and 5' untranslated region from position -1173 to position +130 relative to the transcriptional start site upstream of a firefly luciferase reporter gene in the eukaryotic expression vector pXP1 (described by Nordeen S.K. (1988) *Biotechniques* 6: 454-456). The -1173 to +130 fragment of wild type

- 27 -

TNF- α was obtained as a HindIII/NdeI fragment from the previously described plasmid -1173-CAT (Udalova I.A. et al. (1995) *Doklady Akademii Nauk.* **342**: 413-417). The corresponding fragment containing the G to A substitution at position -376 was synthesised by site directed mutagenesis in the construct -1173-CAT, using previously published methodology (Stuber F. et al (1996) *J. Inflamm.* **46**: 42-50).

10 **(b) Transient transfection of MonoMac 6 cells**

Transfection of MonoMac 6 cells was carried out using the modified DEAE-dextran method (Shakhov, A et al. (1990) *J. Exp. Med.* **171**: 35-47) using 100 μ g/ml DEAE-dextran and 2 μ g plasmid DNA. The cells were allowed to recover for 24 hours post-transfection and then either left unstimulated or stimulated with 200ng/ml LPS. The cells were harvested after 40 hours with cell lysate volumes adjusted to equalise total cellular protein content between samples. Firefly luciferase activity was measured using a manual Turner TD20e luminometer (Promega).

25 **Results**

The results of transient transfection experiments using MonoMac6 cells are summarised in Table 1 below:

Table 1

	No Insert	376G	376A	P Value*
Basal	0.23±0.07	16.1±1.7	21.7±2.4	0.002
LPS- stimulated	0.25±0.1	189.9±19.3	200.3±13.7	ns
Ratio of LPS stimulated: basal	1.1±0.5	12.3±1.4	10.1±1.5	0.007

*P values shown for comparison of 376G and 376A constructs by two-tailed paired t-test. MonoMac6 cells were transfected with pXP1 vector containing no insert, which served as a negative control, or with one of two allelic forms of the TNF- α promoter region which differed by a single nucleotide substitution at position -376, either G (denoted as 376G) or A (denoted as 376A). The mean of 7 independent transisient transfection experiments is shown (\pm SEM) using two independent plasmid preparations. Cells were unstimulated to determine basal expression or stimulated with a high dose of LPS (200ng/ml). Luciferase activity of cell lysates was determined using a luminometer (with results corrected for total cell protein) and is expressed as luminometer units per mg protein.

Example 6 Clinical case-control studies.

(A) Study design

Children under 10 years of age were recruited to two independent case-control studies in the Gambia and Kenya. The Gambian study was carried out near Banjul and was hospital based as described previously (Hill, A.V.S. et al. (1991) *Nature* **352**: 595-600). In the Kenyan study cases of severe malaria recruited at the

- 29 -

Kilifi District Hospital were matched for age with community controls (Newbold, C. et al. (1997) *J. Trop. Med. Hygiene*. **57**: 398; Snow, R.W. et al. (1993) *Trans. R. Soc. Trop. Med. Hyg.* **87**: 386-390). The studies were approved by the MRC/Gambian joint ethical committee and the KEMRI ethical committee. Cerebral malaria was defined as a Blantyre coma score of 2 or less (Molyneux, M.E. et al. (1989) *Q. J. Med.* **71**: 441-459) persisting for more than 30 minutes after any convulsions had ceased in a child with *P. falciparum* parasites on thick blood film and no evidence of meningitis or any other cause of coma. The Gambian control group comprised children seen in clinic with a variety of mild non-malarial illnesses that did not require admission to hospital. The Kenyan control group comprised healthy age-matched children from the same community as the index cases, recruited irrespective of presence or absence of malarial parasitaemia. The mean age of children in the Gambian study was 3.9 years for cerebral malaria cases and 2.9 years for the controls, whilst in the Kenyan study it was 2.7 years and 2.5 years respectively. Data was also analysed from Gambian children with severe malarial anaemia (haemoglobin <5g/dl) or mild malaria (defined as an uncomplicated febrile illness in a child with asexual *P. falciparum* parasites on the blood film without any other satisfactory explanation for the fever).

(B) Genotyping of TNF₃₇₆ and TNF₂₃₈

Genotyping was carried out on randomised samples of genomic DNA, blind to disease outcome, by PCR ELISA (Boehringer Mannheim) using differential hybridisation with sequence specific probes. Nested PCR amplification generated a digoxigenin labelled 375

- 30 -

nucleotide product spanning position -558 to position -183 of the TNF- α promoter using 100ng of genomic DNA as a template. This product was alkaline denatured and hybridised in streptavidin coated microtitre plates with allele-specific 5' biotinylated oligonucleotide probes at 55°C for 2 hours. Allele-specific capture probes used for TNF₋₂₃₈ were 5'-CCTCGGAATCgGAGCAGGGA and 5'-CCTCGGAATCaGAGCAGGGA at 2.5 pmol/ml; for TNF₋₃₇₆ 5'-CTGTCTGGAAgTTAGAAGGA and 5'-CTGTCTGGAAaTTAGAAGGA at 15 pmol/ml. A split plate design was used for each polymorphism, including positive and negative controls. Hybridised DNA was labelled by incubation with 2mU anti-digoxigenin peroxidase conjugate for 30 minutes at 37°C. After addition of 0.2mg of ABTS substrate plates were read on an ELISA plate reader at 405nm (reference filter 492nm). The accuracy of genotyping data obtained by PCR ELISA was confirmed by DNA sequencing.

20 **Results**

Results from the Gambian case control study are summarised in Table 2 below:

25 Table 2

	Cerebral malaria	Severe malaria anaemia	Mild malaria	Non- malaria controls
TNF_{-376A}				
n	384	132	349	371
Heterozygotes	24 (6.3%)	5 (3.8%)	13 (3.7%)	9 (2.4%)
30 Homozygotes	1 (0.3%)	0	1 (0.3%)	1 (0.3%)

n number of individuals in each clinical category for the Gambian case-control study. In a 2x2 analysis

- 31 -

possession of the $\text{TNF}_{-376\text{A}}$ allele was associated with an odds ratio of 2.5 (95% CI 1.2-5.3) $\chi^2=6.21$ $P=0.013$) for cerebral malaria versus non-malaria controls.

5 **Example 7 Affinity purification of proteins**

Proteins binding to the α and β sites of the $\text{TNF-}\alpha$ promoter are present in crude nuclear extracts prepared from the human monocyte cell line U937
10 (CellBank, Dunn School of Pathology, University of Oxford; refs International Journal of Cancer, 17, 565-577, (1976) and Journal of Immunology 125, 6-12 (1980)). This cell line is used as a starting material for purification of the 21kDa and 30kDa
15 proteins in preference to MonoMac6 as it is more suitable for large scale cell culture work.

1) Enrichment of specific proteins binding to sites α and β using affinity chromatography

20 Generic partial purification of DNA binding proteins has been reported using a variety of ion exchange and other resins, for example DNA-cellulose, phosphocellulose, DE52, wheat germ agglutinin and CMS2
25 (see Methods in Enzymology 208, 10-23 (1991) for examples of proteins purified by DNA affinity). The inventors have found that proteins binding to site α and site β can be enriched specifically by heparin sepharose and phosphocellulose (P11), using as a read
30 out for successful binding an electrophoretic mobility shift assay (EMSA) using radiolabelled probes containing the specific DNA recognition sequences for the respective proteins. EMSA methodology was described previously in Example 3. Probe design also
35 as documented previously:

- 32 -

site α 5'agctGTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA
 5'agctTAACTTCCAGACAGGATGCAGGAAAAAGATAGAAC

5 site β 5'agctTAGAAGGAAACAGACCACAGACCTG
 5'agctCAGGTCTGTGGTCTGTTTCCTTCTA

Crude nuclear extract prepared from unstimulated U937 cells will bind to heparin sepharose CL-6B (Pharmacia) and to phosphocellulose (P11) (Whatman) using BC100
 10 buffer (20mM Hepes, 20% glycerol, 0.2mM EDTA and 100mM NaCl). The active material containing the protein(s) binding to site β are eluted by applying a salt gradient from 100 to 2000mM with enriched material eluted at 250-350mM (heparin sepharose) and 500-600mM
 15 (P11) BC buffer. Figure 11 illustrates this for P11 in an EMSA: lane 1 crude nuclear extract, lane 2 crude nuclear extract following incubation with P11 (demonstrating the protein is absent as it has bound to P11), lane 3 low salt buffer wash of P11
 20 (demonstrating the protein remains bound to P11), lane 4 enriched material eluted from P11 with high salt buffer.

2) DNA affinity purification

25 Following heparin sepharose/P11 purification, the proteins binding to sites α and β are recovered by DNA affinity purification using site-specific oligonucleotide probes. The generic methodology for purification using biotinylated oligonucleotide probes
 30 linked to streptavidin coated beads has been described (Nucleic Acids Research 17, 6253-6267 (1989)). For site β the following biotinylated probe is synthesised:

35 5'agctTAGAAGGAAACAGACCACAGACCTG
 ATCTTCCTTTGTCTGGTGTCTGGAC-biotin-5'

- 33 -

For site α the following biotinylated probe is synthesised:

5'agctGTTCTATCTTTTTCTGCATCCTGTCTGGAAGTTA
 5 CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-biotin-5'

Procedures for the labelling of oligonucleotides with biotin are well known in the art.

The appropriate double-stranded probe is added to streptavidin-coated Dynabeads™ (M-280) to which the probe becomes strongly bound. Incubation of the probe-bead complex with the enriched material generated in part 1) allows binding of the proteins specific to the site of interest defined by the sequence of the oligonucleotide probe. Figure 12 shows the result of such a purification step for site β when the products are used in an EMSA (lane 1 heparin sepharose purified material, lane 2 bead-DNA purified material).

SEQUENCE LISTING

1. Sequence ID No. 1 corresponds to the nucleotide sequence of the α site of the human TNF- α promoter illustrated in Figure 1a (TNF-_{376G} allele).
2. Sequence ID No. 2 corresponds to the nucleotide sequence of the α site of the human TNF- α promoter illustrated in Figure 1b (TNF-_{376A} allele).
3. Sequence ID No. 3 corresponds to the nucleotide sequence of the β site of the human TNF- α promoter illustrated in Figure 2.
4. Sequence ID No. 4 is the nucleotide sequence of

- 34 -

an oligonucleotide probe corresponding to a region of the human TNF- α promoter including the α site.

- 5 5. Sequence ID No. 5 is the nucleotide sequence of an oligonucleotide probe corresponding to a region of the human TNF- α promoter including the β site.
- 10 6. Sequence ID No. 6 is the nucleotide sequence of an allele-specific oligonucleotide probe specific for the TNF_{-376G} allele.
- 15 7. Sequence ID No. 7 is the nucleotide sequence of an allele-specific oligonucleotide probe specific for the TNF_{-376A} allele.

Claims:

1. A sequence-specific DNA binding protein which is capable of binding specifically both to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 1 and to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 2.
2. A sequence-specific DNA binding protein as claimed in claim 1 having an electrophoretic mobility equivalent to a protein of molecular weight 21 +/- 5kDa when run on an SDS PAGE denaturing gel.
3. A sequence-specific DNA binding protein as claimed in claim 1 or claim 2 which is obtainable by
- (a) preparing a crude nuclear extract from the human monocyte cell line U937;
 - (b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;
 - (c) applying a salt gradient from 100 to 2000mM to the column;
 - (d) collecting a fraction of the eluate which is enriched for the said sequence-specific DNA binding protein;;
 - (e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes comprising the following sequence:
- 5'-GTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA
CAAGATAGAAAAAGGACGTAGGACAGACCTTCAAT-5'
- to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity probe; and
- (f) recovering the sequence-specific binding

- 36 -

protein from the complexes formed in step (e).

4. A sequence-specific DNA binding protein which is capable of binding specifically to a DNA molecule having the sequence of nucleotides illustrated in SEQ ID NO: 3.

5. A sequence-specific DNA binding protein as claimed in claim 4 having an electrophoretic mobility equivalent to a protein of molecular weight 30 +/- 5kDa when run on an SDS PAGE denaturing gel.

6. A sequence-specific DNA binding protein as claimed in claim 4 or claim 5 which is obtainable by:

(a) preparing a crude nuclear extract from the human monocyte cell line U937;

(b) applying the nuclear extract of part (a) to a column of heparin sepharose CL-6B or phosphocellulose P11;

(c) applying a salt gradient from 100 to 2000mM to the column;

(d) collecting the material eluted at 250-350mM salt for heparin sepharose or 500-600mM salt for P11 phosphocellulose;

(e) incubating the enriched material obtained in step (d) with double-stranded DNA affinity probes comprising the following sequence:

5'-TAGAAGGAAACAGACCACAGACCTG
ATCTTCCTTTGTCTGGTGTCTGGAC-5'

to allow the formation of complexes of the sequence-specific DNA binding protein bound to the DNA affinity probe; and

(f) recovering the sequence-specific binding protein from the complexes formed in step (e).

- 37 -

7. An isolated nucleic acid consisting of the sequence of nucleotides illustrated in SEQ ID NO: 1.

5 8. An isolated nucleic acid consisting of the sequence of nucleotides illustrated in SEQ ID NO: 2.

10 9. An isolated nucleic acid as claimed in claim 7 or claim 8 or a fragment thereof which is capable of specifically binding to the DNA binding protein of any one of claims 1 to 3.

10. An isolated nucleic acid consisting of the sequence of nucleotides illustrated in SEQ ID NO: 3.

15 11. An isolated nucleic acid as claimed in claim 10 or a fragment thereof which is capable of specifically binding to the DNA binding protein of any one of claims 4 to 6.

20 12. A reporter gene expression construct comprising:

a reporter gene encoding a transcriptional and/or translational product which can be directly or indirectly detected; and

25 a transcriptional control element comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequence from the TNF- α promoter, the transcriptional control element being operably linked to the reporter gene.

30 13. A reporter gene expression construct as claimed in claim 12 which further comprises one or more *cis*-acting promoter or enhancer elements from a heterologous promoter.

14. Cells transformed or transfected with the

- 38 -

reporter gene expression construct of claim 12 or claim 13.

5 15. A method of identifying a compound capable of modulating TNF- α gene expression, which method comprises:

10 contacting a fragment of DNA comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequences from a TNF- α promoter with a sample of the compound and detecting any specific binding of the compound to the fragment of DNA.

15 16. A method of identifying compounds capable of modulating TNF- α gene expression, which method comprises:

20 comparing the difference in the amount of reporter gene expression in the cells of claim 14 in the presence of the compound with the amount of reporter gene expression in the absence of the compound and/or with the amount of reporter gene expression in cells transfected with a control reporter gene expression construct which does not
25 contain one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, whereby compounds capable of modulating TNF- α gene expression are identified.

30 17. A method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

35 (a) contacting an aqueous solution comprising a DNA binding protein as claimed in any one of claims 1 to 3 with a sample of the compound to form a reaction mixture;

(b) contacting the reaction mixture from part

- 39 -

(a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2; and

5 (c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

10 18. A method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

(a) contacting an aqueous solution comprising the DNA binding protein claimed in any one of claims 1 to 3 and the transcription factor protein Oct-1 with a sample of the compound to form a reaction mixture ;

15 (b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2; and

(c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

19. A method of identifying compounds capable of modulating TNF- α gene expression, which method comprises steps of:

25 contacting an aqueous solution comprising the DNA binding protein claimed in any one of claims 4 to 6 with a sample of the compound to form a reaction mixture;

30 (b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3; and

(c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

35

20. A method as claimed in any one of claims 17 to 19 wherein said DNA fragment is radiolabelled and

- 40 -

the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment is determined by electrophoretic mobility shift assay.

5 21. A method of identifying compounds capable of modulating TNF- α gene expression, which method comprises:

 contacting a DNA-protein complex comprising one of the following DNA/protein combinations:

- 10 (i) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2 and the DNA binding protein claimed in any one of claims 1 to 3,
- 15 (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3 and the DNA binding protein claimed in any one of claims 4 to 6,
- 20 (ii) a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2, the DNA binding protein claimed in any one of claims 1 to 3 and the transcription factor protein Oct-1, with a sample of the compound and observing whether the DNA-protein complex is disrupted following contact with the compound.

25

 22. A compound capable of modulating TNF- α gene expression, which compound has been identified using the method of any one of claims 15 to 21.

30

 23. A nucleic acid molecule consisting of the sequence of nucleotides illustrated in SEQ ID NO: 4.

 24. A nucleic acid molecule as claimed in claim 23 which is a double-stranded DNA molecule.

35

 25. A material comprising the nucleic acid molecule of claim 23 or claim 24 attached to a solid

- 41 -

matrix or support.

26. A material as claimed in claim 25 wherein
the nucleic acid molecule is labelled with biotin and
5 is attached to the solid support or matrix via a
biotin/streptavidin binding interaction.

27. Use of the material claimed in claim 25 or
claim 26 in a procedure for purifying a sequence-
10 specific DNA binding protein as defined in any one of
claims 1 to 3.

28. A nucleic acid molecule consisting of the
sequence of nucleotides illustrated in SEQ ID NO: 5.
15

29. A nucleic acid molecule as claimed in claim
28 which is a double-stranded DNA molecule.

30. A material comprising the nucleic acid
20 molecule of claim 28 or claim 29 attached to a solid
matrix or support.

31. A material as claimed in claim 30 wherein
the nucleic acid molecule is labelled with biotin and
25 is attached to the solid support or matrix via a
biotin/streptavidin binding interaction.

32. Use of the material claimed in claim 30 or
claim 31 in a procedure for purifying a sequence-
30 specific DNA binding protein as defined in any one of
claims 4 to 6.

33. A method of screening human individuals for
predisposition to cerebral malaria, which method
35 comprised screening for the presence of a G to A
transition polymorphism at position -376 in the
promoter region of the TNF- α gene.

- 42 -

34. A method as claimed in claim 33 wherein said screening for the presence of a G to A transition polymorphism at position -376 in the promoter region of the TNF- α gene is carried out using PCR ELISA.

5

35. A method as claimed in claim 34 wherein said PCR ELISA is carried out using allele-specific oligonucleotide probes having the following sequences:

5'-CTGTCTGGAAGTTAGAAGGA (SEQ ID NO: 6)

10 5'-CTGTCTGGAAATTAGAAGGA (SEQ ID NO: 7)

36. A method of identifying a compound capable of disrupting a DNA/protein interaction occurring at the TNF α promoter, which method comprises:

15 contacting a fragment of DNA comprising one or more of the sequences of nucleotides illustrated in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 in the substantial absence of any other nucleotide sequences from a TNF- α promoter with a sample of the compound
20 and detecting any specific binding of the compound to the fragment of DNA.

37. A method of identifying compounds capable of disrupting a DNA/protein interaction occurring at the TNF α promoter, which method comprises steps of:

25

(a) contacting an aqueous solution comprising a DNA binding protein as claimed in any one of claims 1 to 3 with a sample of the compound to form a reaction mixture;

30

(b) contacting the reaction mixture from part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 1 or SEQ ID NO: 2; and

(c) observing the presence or absence of
35 complexes comprising said DNA binding protein bound to said DNA fragment.

- 43 -

38. A method of identifying compounds capable of disrupting a DNA/protein interaction occurring at the TNF α promoter, which method comprises steps of:

5 (a) contacting an aqueous solution comprising the DNA binding protein claimed in any one of claims 1 to 3 and the transcription factor protein Oct-1 with a sample of the compound to form a reaction mixture ;

10 (b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 2; and

(c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

15 39. A method of identifying compounds capable of disrupting a DNA/protein interaction occurring at the TNF α promoter, which method comprises steps of:

20 contacting an aqueous solution comprising the DNA binding protein claimed in any one of claims 4 to 6 with a sample of the compound to form a reaction mixture;

(b) contacting the reaction mixture of part (a) with a DNA fragment comprising the sequence of nucleotides illustrated in SEQ ID NO: 3; and

25 (c) observing the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment.

30 40. A method as claimed in any one of claims 37 to 39 wherein said DNA fragment is radiolabelled and the presence or absence of complexes comprising said DNA binding protein bound to said DNA fragment is determined by electrophoretic mobility shift assay.

35 41. A method of identifying a compound capable of disrupting a DNA/protein interaction occurring at the TNF α promoter, which method comprises:

contacting a DNA-protein complex comprising one of the following DNA/protein combinations:

- 20

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/68, C07K 14/47, A61K 35/00, C12N 5/10, 15/85	A1	(11) International Publication Number: WO 00/47768 (43) International Publication Date: 17 August 2000 (17.08.00)
(21) International Application Number: PCT/GB00/00414 (22) International Filing Date: 9 February 2000 (09.02.00) (30) Priority Data: 9902919.1 9 February 1999 (09.02.99) GB (71) Applicant (for all designated States except US): ISIS INNOVATION LTD. [GB/GB]; 2 South Parks Road, Oxford OX1 3UB (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): KNIGHT, Julian, Charles [GB/GB]; The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7BN (GB). KWIATKOWSKI, Dominic, Peter [GB/GB]; University Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU (GB). (74) Agent: BOULT WADE TENNANT; Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MODULATOR OF INFLAMMATION <div style="text-align: center; padding: 20px;">5'-ACAGACCACAGACC</div> (57) Abstract <p>Two novel DNA binding proteins are provided which bind specifically to DNA target sites within the promoter region of the TNF-α gene. Also provided are screening methods based on this DNA-protein interaction which may be used to identify compounds which modulate the expression of TNF-α and a genetic screen for susceptibility to inflammatory disease based upon screening for a single nucleotide polymorphism in the TNF-α promoter.</p>		

117

FIG. 1a.

5'-GCATCCTGTCTGGAAGTT


FIG. 1b.

5'-GCATCCTGTCTGGAAATT

FIG. 2.

5'-ACAGACCACAGACC

FIG. 3.




2/7

FIG. 4.


	404nt	374nt
	TTCTAGTTCATCTTTTTCCTGCATCCTGTCTGGAAGTTAGAAGGAA	
Probe α_G	GTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA	
Probe α_A	GTTCTATCTTTTTCCTGCATCCTGTCTGGAAGTTA	
Probe distal α	GTTCTATCTTTTTCCTGCATCC	
Probe proximal α_G	GCATCCTGTCTGGAAGTTA	
Probe proximal α_A	GCATCCTGTCTGGAAGTTA	

FIG. 5.



3/7

FIG. 6.




4/7

FIG. 7.

	-372nt	-352nt
	TAGAAGGAAACAGACCACAGACCTGGTCCCCAAAAG	
Probe β	TAGAAGGAAACAGACCACAGACCTG	
Probe β -1	ACAGACCACAGACCTGGTCCC	
Probe β -2	CACAGACCTGGTCCCCAAAAG	

FIG. 8.






FIG. 10.

Site α_G	agctGTTCTATCTTTQTCCQGCATCCQGTCQGGAAAGQTA agctQAACQQCCAGACAGGAQGCAGGAAAAAGAQAGAAC
Site α_A	agctGTTCTATCTTTQTCCQGCATCCQGTCQGGAAAQTA agctQAAQTQCCAGACAGGAQGCAGGAAAAAGAQAGAAC
Site β	agctQAGAAGGAAACAGACCACAGACCQG agctCAGGTCTGQGGQCTGQTQCCQTCTA

6/7

FIG. 11.

1 2 3 4



7/7

FIG. 12.

1 2



DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

MODULATOR OF INFLAMMATION

the specification of which is attached hereto unless the following is checked:

[X] was filed on August 7, 2001, as United States Application No. 09/890,891, and bearing attorney docket no. I0317/7001.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or section 365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign PCT International Application(s) and any priority claims under 35 U.S.C. §§119 and 365(a),(b):

			Priority Claimed	
<u>GB 9902919.1</u> (Number)	<u>United Kingdom</u> (Country-if PCT, so indicate)	<u>February 9, 1999</u> (DD/MM/YY Filed)	<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO
<u> </u> (Number)	<u> </u> (Country-if PCT, so indicate)	<u> </u> (DD/MM/YY Filed)	<input type="checkbox"/> YES	<input type="checkbox"/> NO
<u> </u> (Number)	<u> </u> (Country-if PCT, so indicate)	<u> </u> (DD/MM/YY Filed)	<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

(Application Number)	(filing date)
(Application Number)	(filing date)

PCT/GB00/00414

(Application No.)

February 9, 2000

(filing date)

Published as WO 00/47768

(status-patented, pending, abandoned)

(Application No.)

(filing date)

(status-patented, pending, abandoned)

(PCT Appl. No.)

(U.S. Ser. No.)

(PCT filing date)

(status-patented,pending,abandoned)

Robert M. Abrahamsen	<u>40,886</u>
Konstantinos Andrikopoulos	<u>48,915</u>
Eric Amundsen	<u>46,518</u>
John N. Anastasi	<u>37,765</u>
Ilan Barzilay	<u>46,540</u>
Carole Boelitz	<u>P-48,958</u>
Gary S. Engelson	<u>35,128</u>
Neil P. Ferraro	<u>39,188</u>
Thomas G. Field III	<u>45,596</u>
Stephen R. Finch	<u>42,534</u>
Edward R. Gates	<u>31,616</u>
Richard F. Giunta	<u>36,149</u>
Lawrence M. Green	<u>29,384</u>
George L. Greenfield	<u>17,756</u>
James M. Hanifin, Jr.	<u>39,213</u>
Steven J. Henry	<u>27,900</u>

Jason M. Honeyman	<u>31,624</u>
Robert E. Hunt	<u>39,231</u>
Ronald J. Kransdorf	<u>20,004</u>
Peter C. Lando	<u>34,654</u>
M. Brad Lawrence	<u>47,210</u>
Helen C. Lockhart	<u>39,248</u>
Matthew B. Lowrie	<u>38,228</u>
William R. McClellan	<u>29,409</u>
Daniel P. McLoughlin	<u>46,066</u>
James H. Morris	<u>34,681</u>
Timothy J. Oyer	<u>36,628</u>
Edward F. Perlman	<u>28,105</u>
Elizabeth R. Plumer	<u>36,637</u>
Michael J. Pomianek	<u>46,190</u>
Randy J. Pritzker	<u>35,986</u>

Edward J. Russavage	43,069
Stanley Sacks	19,900
Christopher S. Schultz	37,929
Robert A. Skrivanek, Jr.	41,316
Alan W. Steele	45,128
Mark Steinberg	40,829
Joseph Teja, Jr.	45,157
Maryanne Trevisan	48,207
John R. Van Amsterdam	40,212
Robert H. Walat	46,324
Kristin D. Wheeler	43,583
Lisa E. Winsor	44,405
David Wolf	17,528
Douglas R. Wolf	36,971

Address all telephone calls to Elizabeth R. Plumer at telephone no. (617) 720-3500. Address all correspondence to:

Elizabeth R. Plumer
c/o Wolf, Greenfield & Sacks, P.C.,
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment,

or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

x Julian Knight
Inventor's signature 1-00
Full name of first inventor: JULIAN CHARLES KNIGHT
Citizenship: Great Britain GBX
Residence: Oxford, Great Britain
Post Office Address:

x 25/9/01
Date

x Dominic Kwiatkowski
Inventor's signature 2-00
Full name of second inventor: DOMINIC PETER ZWIATKOWSKI
Citizenship: Great Britain GBX
Residence: Oxford, Great Britain
Post Office Address:

x 14/9/01
Date

SEQUENCE LISTING

<110> ISIS INNOVATION LIMITED

<120> MODULATOR OF INFLAMMATION

<130> SCB/50929/001

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 18

<212> DNA

<213> Homo sapiens

<400> 1

gcatacctgtc tggaaagt
18

<210> 2

<211> 18

<212> DNA

<213> Homo sapiens

<400> 2

gcatacctgtc tggaaatt
18

<210> 3

<211> 14

<212> DNA

<213> Homo sapiens

<400> 3

acagaccaca gacc
14

<210> 4

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide containing binding site for the
21kDa DNA binding protein

<400> 4

gttctatctt tttcctgcat cctgtctgga agtta
35

<210> 5

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide containing binding site for the
30kDa DNA binding protein

<400> 5

tagaaggaaa cagaccacag acctg
25

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide probe for PCR ELISA

<400> 6

ctgtctggaa gtagaagga
20

<210> 7

<211> 20

<212> DNA


<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide probe for PCR ELISA

<400> 7

ctgtctggaa attagaagga
20

[illegible]

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

~~X~~ **Scanned copy is best available.** Drawings are dark.